Stock Code:3105

WIN SEMICONDUCTORS CORP. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

With Independent Auditors' Review Report For the Nine Months Ended September 30, 2022 and 2021

Address: No.69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan

Telephone: 886-3-397-5999

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

		Contents	Page				
	1. Cov	er Page	1				
	2. Tabl	e of Contents	2				
	3. Inde	pendent Auditors' Review Report	3				
	4. Consolidated Balance Sheets						
	5. Cons	solidated Statement of Comprehensive Income	5				
	6. Con	solidated Statement of Changes in Equity	6				
	7. Cons	solidated Statement of Cash Flows	7				
8. Notes to the Consolidated Financial Statements							
	(1)	Company history	8				
	(2)	Approval date and procedures of the consolidated financial statements	8				
	(3)	New standards, amendments and interpretations adopted	8~9				
	(4)	Summary of significant accounting policies	10~11				
	(5)	Significant accounting assumptions and judgments, and major sources of estimation uncertainty	12				
	(6)	Explanation of significant accounts	12~59				
	(7)	Related-party transactions	59~60				
	(8)	Pledged assets	61				
	(9)	Commitments and contingencies	61				
	(10)	Losses due to major disasters	62				
	(11)	Subsequent events	62				
	(12)	Other	62				
	(13)	Other disclosures					
		(a) Information on significant transactions	$66 \sim 70$				
		(b) Information on investments	71				
		(c) Information on investment in mainland China	$72 \sim 73$				
		(d) Information on major shareholders	73				
	(14)	Segment information	$64 \sim 65$				



安侯建業假合會計師重務的 KPMG

台北市110615信義路5段7號68樓(台北101大樓) 68F., TAIPEI 101 TOWER, No. 7, Sec. 5, Xinyi Road, Taipei City 110615, Taiwan (R.O.C.) 電話 Tel + 886 2 8101 6666 傳真 Fax + 886 2 8101 6667 網址 Web home.kpmg/tw

Independent Auditors' Review Report

To the Board of Directors of WIN Semiconductors Corp.:

Introduction

We have reviewed the accompanying consolidated balance sheets of WIN Semiconductors Corp. and subsidiaries as of September 30, 2022 and 2021, and the related consolidated statements of comprehensive income for the three months and nine months ended September 30, 2022 and 2021, as well as the changes in equity and cash flows for the nine months ended September 30, 2022 and 2021, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standards ("IASs") 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with Statement of Auditing Standards 65, "Review of Financial Information Performed by the Independent Auditor of the Entity". A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the generally accepted auditing standards and consequently, does not enable us to obtain assurance that we would become aware of any significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews and the review reports of another auditor (please refer to Other Matter Paragraph), nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of WIN Semiconductors Corp. and subsidiaries as of September 30, 2022 and 2021, and of its consolidated financial performance for the three months and nine months ended September 30, 2022 and 2021, and its consolidated cash flows for the nine months ended September 30, 2022 and 2021 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.



Other Matter

We did not review the financial statements for the nine months ended September 30, 2022 and 2021 of certain investments accounted for using the equity method. The financial statements for the nine months ended September 30, 2022 and 2021 were reviewed by another auditor, whose review reports have been furnished to us, and our conclusion, insofar as it relates to the amounts included in these investments, is based solely on the review reports of another auditor. The investment accounted for using the equity method amounted to \$9,622,826 thousand and \$9,187,193 thousand, constituting 13.67% and 12.76% of the consolidated total assets as of September 30, 2022 and 2021, respectively, and the related shares of profit of associates and joint ventures accounted for using the equity method amounted to \$53,469 thousand, \$145,986 thousand, \$286,544 thousand and \$145,986 thousand, respectively, as well as the related shares of other comprehensive income of associates and joint ventures accounted for using the equity method amounted to \$81,504 thousand, \$(17,690) thousand, \$52,153 thousand and \$(17,690) thousand, respectively, constituting 13.40%, 11.19%, 17.56%, 4.31%, 20.43%, (1.36)%, 3.20% and (0.52)% of the consolidated total comprehensive income and loss for the three months and nine months ended September 30, 2022 and 2021, respectively.

The engagement partners on the reviews resulting in this independent auditors' review report are Chia-Chien Tang and Ming-Hung Huang.

KPMG

Taipei, Taiwan (The Republic of China) November 11, 2022

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

Reviewed only, not audited in accordance with the generally accepted auditing standards as of September 30, 2022 and 2021

WIN Semiconductors Corp. and Subsidiaries

Consolidated Balance Sheets

September 30, 2022, December 31, and September 30, 2021

(Expressed in Thousands of New Taiwan Dollars)

	Assets Current assets:	September 30, 2 Amount	<u>%</u>	December 31, 2 Amount	<u>021</u> <u>%</u>	September 30, 2 Amount	<u>2021</u> <u>%</u>		Liabilities and Equity Current liabilities:	September 30, Amount	2022	December 31, 2 Amount	<u>021</u>	September 30, 2 Amount	<u>2021</u>
1100	Cash and cash equivalents (Note 6(a))	\$ 10,880,336	15	16,331,759	22	16,481,962	23	2100	Short-term borrowings (Notes 6(o), 6(ae) and 8)	\$ 18,805		_	_	_	_
1110	Current financial assets at fair value through profit or loss (Note 6(b))			61,875		56,027	-	2120	Current financial liabilities at fair value through profit or loss (Notes 6(b) and 6(q))	597,050		180,497	_	244,860	_
1170	Notes and accounts receivable, net (Notes $6(c)$ and $6(y)$)	1,312,226	2	2,717,560	3	2,087,879	3	2130 2170	Current contract liabilities (Note 6(y)) Notes and accounts payable	214,889 862,882		353,157 2,162,825	- 3	299,967 2,219,460	
1310	Inventories (Note 6(e))	5,510,621	8	6,670,737	9	6,593,956	9	2200	Other payables	2,505,020		4,218,686	6	3,293,399	
1400	Current biological assets (Note 6(f))	54,016	-	138,494	-	119,813	-	2280	Current lease liabilities (Notes 6(r) and 6(ae))	2,303,020		122,882	O	132,042	
1470	Other current assets (Notes 6(d) and 6(n))	296,564		534,427	1	622,248	1	2320	Long-term liabilities, current portion (Notes 6(p),	113,270	-	122,882	-	132,042	-
	Total current assets	18,653,499	26	26,454,852	35	25,961,885		2320	6(ae) and 8)	989,227	2	-	-	5,549,112	8
	Non-current assets:							2399	Other current liabilities	221,614		176,905		191,133	
1510	Non-current financial assets at fair value through								Total current liabilities	5,522,763	8	7,214,952	9	11,929,973	
	profit or loss (Note 6(b))	1,740,257	2	1,822,433	2	1,714,868	2		Non-current liabilities:						
1517	Non-current financial assets at fair value through other comprehensive income (Note 6(b))	1,663,060	2	2,186,577	3	1,930,094	3	2530	Bonds payable (Notes 6(q) and 6(ae))	11,778,373		13,286,639	18	13,244,124	
1550	Investments accounted for using equity method (Note							2540	Long-term borrowings (Notes 6(p), 6(ae) and 8)	16,413,476		15,992,820	22	10,520,340	15
	6(g))	10,351,082		10,405,398	14	9,930,287	14	2570	Deferred tax liabilities	97,047		-	-	-	-
1600	Property, plant and equipment (Notes 6(j), 7 and 8)	31,683,636	45	27,783,997	37	26,646,514	37	2580	Non-current lease liabilities (Notes 6(r) and 6(ae))	976,907		1,034,327	1	1,078,223	
1755	Right-of-use assets (Notes 6(k) and 8)	1,171,096	2	1,255,616	2	1,337,906	2	2600	Other non-current liabilities (Notes 6(ae) and 7)	232,810		243,424		248,298	
1760	Investment property (Note 6(1))	1,049,961	2	1,053,948	1	1,055,277	1		Total non-current liabilities	29,498,613		30,557,210	41	25,090,985	_
1780	Intangible assets (Note 6(m))	585,701	1	641,885	1	568,947	1		Total liabilities	35,021,376	50	37,772,162	50	37,020,958	51
1830	Non-current biological assets (Note 6(f))	318,468	-	389,952	1	348,021	-		Equity (Notes 6(b), 6(g), 6(h), 6(i), 6(q), 6(v) and						
1840	Deferred tax assets	682,412	1	417,116	1	340,026	-	2440	6(w)):						
1915	Prepayments for business facilities	1,943,197	3	2,153,533	3	1,810,364	3	3110	Ordinary shares	4,239,404		4,239,764	6	4,240,414	
1990	Other non-current assets (Notes 6(n) and 8)	555,328	1	328,851		354,337	1	3200	Capital surplus	9,966,730		9,969,914	13	9,958,040	
	Total non-current assets	51,744,198	74	48,439,306	65	46,036,641	64	3300	Retained earnings	18,465,736		19,960,265	27	18,173,899	
								3400	Other equity interests	735,589	1	768,065	1	419,870	
								3500	Treasury shares					(650))
									Total equity attributable to owners of parent	33,407,459	47	34,938,008	47	32,791,573	46
								36XX	Non-controlling interests	1,968,862	3	2,183,988	3	2,185,995	3
									Total equity	35,376,321	50	37,121,996	50	34,977,568	49
	Total assets	\$ <u>70,397,697</u>	100	74,894,158	100	71,998,526	100		Total liabilities and equity	\$ <u>70,397,697</u>	100	74,894,158	100	71,998,526	100

WIN Semiconductors Corp. and Subsidiaries

Consolidated Statement of Comprehensive Income

For the three months and nine months ended September 30, 2022 and 2021

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Common Share)

		For the three n	onths e		r 30	For the nine m	onths er		30
		2022		2021	0/	2022		2021	
4000	Operating revenue (Notes 6(b), 6(g) and 6(y))	** 3,908,742	100	Amount 6,761,092	100	Amount 14,803,060	100	Amount 18,965,104	100
5000	Operating costs (Notes $6(b)$, $6(e)$, $6(f)$, $6(g)$, $6(j)$, $6(k)$, $6(r)$, $6(t)$, $6(w)$,	(3,284,408)	(84)	(4,137,696)	(61)	(10,863,858)	<u>(73</u>)	(12,117,650)	(64)
3000	6(z), 7 and 12)								
	Gross profit from operating	624,334	<u>16</u>	2,623,396	39	3,939,202	27	6,847,454	36
	Operating expenses (Notes 6(c), 6(j), 6(k), 6(l), 6(r), 6(t), 6(w), 6(z), 7 and 12):								
6100	Selling expenses	(89,053)	(2)	(89,327)	(1)	(270,709)	(2)	(269,955)	(1)
6200	Administrative expenses	(286,570)	(7)	(406,544)	(6)	(1,004,892)	(7)	(1,167,394)	(6)
6300	Research and development expenses	(448,447)	(12)	(317,806)	(5)	(1,199,886)	(8)	(995,772)	(5)
6450	Losses on expected credit impairment	(705)	-	(187)	-	(704)	_	(125)	_
	Total operating expenses	(824,775)	(21)	(813,864)	(12)	(2,476,191)	(17)	(2,433,246)	(12)
	Net operating income (loss)	(200,441)	(5)	1,809,532	27	1,463,011	10	4,414,208	24
	Non-operating income and expenses (Notes 6(b), 6(g), 6(j), 6(q), 6(r), 6(aa) and 7):								
7100	Interest income	21,541	1	6,923	-	42,905	_	27,478	-
7010	Other income	35,948	1	11,766	-	207,099	1	40,952	_
7020	Other gains and losses	473,629	12	(9,228)	-	278,102	2	53,290	-
7050	Finance costs	(84,708)	(2)	(80,825)	(1)	(246,561)	(1)	(223,839)	(1)
7060	Share of profit (loss) of associates and joint ventures accounted for using equity method, net	53,359	1	99,484	1	214,210	1	38,437	-
	Total non-operating income and expenses	499,769	13	28,120		495,755	3	(63,682)	(1)
7900	Profit before tax	299,328	8	1,837,652	27	1,958,766	13	4,350,526	23
7950	Tax expense (Note 6(u))	(54,594)	(2)	(341,712)	<u>(5</u>)	(383,803)	(2)	(829,888)	(4)
	Profit	244,734	6	1,495,940	22	1,574,963	11	3,520,638	19
8300	Other comprehensive income:								
8310	Components of other comprehensive income that will not be reclassified to profit or loss (Notes 6(g) and 6(v))								
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	(98,567)	(2)	(164,100)	(3)	(494,755)	(3)	40,243	-
8320	Share of other comprehensive income of associates and joint ventures	962				1 200			
8349	accounted for using equity method Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	- 902	_	-	_	1,399	-	-	-
	Total components of other comprehensive income (loss) that will not be reclassified to profit or loss	(97,605)	(2)	(164,100)	(3)	(493,356)	(3)	40,243	
8360	Components of other comprehensive income that will be reclassified to profit or loss (Notes 6(g) and 6(v))	,							
8361	Exchange differences on translation of foreign financial statements	211,031	5	(9,433)	_	568,472	3	(162,957)	(1)
8370	Share of other comprehensive income of associates and joint ventures accounted for using equity method	40,794	1	(18,161)	_	(18,600)	-	(13,843)	-
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss					-	_	-	_
	Total components of other comprehensive income (loss) that will be reclassified to profit or loss	251,825	6	(27,594)		549,872	3	(176,800)	(1)
8300	Other comprehensive income, net	154,220	4	(191,694)	<u>(3</u>)	56,516		(136,557)	<u>(1</u>)
8500	Total comprehensive income	\$ 398,954	10	1,304,246	19	1,631,479	11	3,384,081	18
	Profit (loss) attributable to:								
8610	Profit attributable to owners of parent	\$ 351,809	9	1,551,965	23	1,878,060	13	3,683,073	20
8620	Profit (losses) attributable to non-controlling interests	(107,075)	<u>(3</u>)	(56,025)	<u>(1</u>)	(303,097)	<u>(2</u>)	(162,435)	<u>(1</u>)
		\$ <u>244,734</u>	6	1,495,940	22	1,574,963	11	3,520,638	19
	Comprehensive income (loss) attributable to:								
8710	Comprehensive income, attributable to owners of parent	\$ 482,093	12	1,362,084	20	1,857,817	13	3,568,854	19
8720	Comprehensive income (loss), attributable to non-controlling interests	(83,139)	<u>(2</u>)	(57,838)	<u>(1</u>)	(226,338)	<u>(2</u>)	(184,773)	<u>(1</u>)
		\$ 398,954	10	1,304,246	19	1,631,479	11	3,384,081	18
	Earnings per common share (expressed in New Taiwan dollars) (Note 6(x))								
9750	Basic earnings per share	\$0.83		3.67		4.43		8.71	
9850	Diluted earnings per share	\$ 0.25		3.64		4.41		8.64	

WIN Semiconductors Corp. and Subsidiaries

Consolidated Statement of Changes in Equity

For the nine months ended September 30, 2022 and 2021

(Expressed in Thousands of New Taiwan Dollars)

					Equity att	ributable to owr	iers of parent						
							Other equi	ty interests					
							Unrealized						
							gains						
							(losses) on						
				Retained earnings		Exchange	financial assets	Other					
						differences on	measured at	unearned					
					m	translation of	fair value	compensation			Total equity		
	Ordinary	Capital		Unappropriated	Total retained	foreign financial	through other comprehensive	for restricted shares of	Total other	Treasury	attributable to owners of N	Non-controlling	
	shares		Logal recerve	retained earnings	earnings	statements	income	employees	equity interests	shares	parent	interests	Total equity
Balance at January 1, 2021	\$ 4,240,564	9,323,098	2,515,700	14,485,321	17,001,021	(202,205)				snares	34,077,586	1,652,866	35,730,452
Appropriation and distribution of retained earnings:	ψ <u>1,210,301</u>	7,323,070	2,515,700	11,105,521	17,001,021	(202,203	3,700,010	(03,730)	3,312,703		31,077,300	1,032,000	33,730,132
Legal reserve appropriated			657,022	(657,022)									
Cash dividends of ordinary shares	-	-	037,022	(4,240,414)	(4,240,414)	-	-	-	-	-	(4,240,414)	-	(4,240,414)
Cash dividends of ordinary shares			657,022		(4,240,414)								(4,240,414)
P. C. (1			037,022	(4,897,436)	$\overline{}$						(4,240,414)	- (1.62.425)	
Profit (losses) for the nine months ended September 30, 2021	-	-	-	3,683,073	3,683,073	- (154.460)	- 40.242	-	(114.210)	-	3,683,073	(162,435)	
Other comprehensive income for the nine months ended September 30, 2021					-	(154,462)			(114,219)		(114,219)	(22,338)	
Total comprehensive income for the nine months ended September 30, 2021				3,683,073	3,683,073	(154,462)	40,243		(114,219)		3,568,854	(184,773)	3,384,081
Changes in ownership interest in subsidiaries	-	3,654	-	(25,344)	(25,344)	-	-	-	-	-	(21,690)	-	(21,690)
Compensation cost arising from restricted shares of employees	-	-	-	39	39	-	-	54,743	54,743	-	54,782	-	54,782
Purchase and retirement of restricted shares of stock for employees	(150)	150	-	-	-	-	-	-	-	-	-	-	-
Purchase and wait for retirement of restricted shares of stock for employees	-	(9,913)	-	-	-	-	-	10,563	10,563	(650)	-	-	-
Recognition of equity component of convertible bonds issued	-	639,583	-	-	-	-	-	-	-	-	639,583	-	639,583
Changes in equity of associates accounted for using equity method	-	1,137	-	(1,288,596)	(1,288,596)	-	-	-	-	-	(1,287,459)	-	(1,287,459)
Stock option compensation cost of subsidiary	-	331	-	-	-	-	-	-	-	-	331	230	561
Disposal of investments in equity instruments designated at fair value through	i												
other comprehensive income	-	-	-	3,044,120	3,044,120	-	(3,044,120)) -	(3,044,120)	-	-	-	-
Changes in non-controlling interests												717,672	717,672
Balance at September 30, 2021	\$ 4,240,414	9,958,040	3,172,722	15,001,177	18,173,899	(356,667	776,969	(432)	419,870	(650)	32,791,573	2,185,995	34,977,568
Balance at January 1, 2022	\$ 4,239,764	9,969,914	3,172,722	16,787,543	19,960,265	(269,409)	1,044,071	(6,597)	768,065		34,938,008	2,183,988	37,121,996
Appropriation and distribution of retained earnings:													
Legal reserve appropriated	_	_	719,966	(719,966)	_	_	_	_	_	_	_	_	_
Cash dividends of ordinary shares	_	_	_	(3,391,811)	(3,391,811)	_	_	_	_	_	(3,391,811)	_	(3,391,811)
,			719,966	(4,111,777)	(3,391,811)						(3,391,811)		(3,391,811)
Profit (losses) for the nine months ended September 30, 2022			-	1,878,060	1,878,060						1,878,060	(303,097)	
Other comprehensive income for the nine months ended September 30, 2022	_		_	-	-	473,113	(493,356)		(20,243)		(20,243)	76,759	56,516
Total comprehensive income for the nine months ended September 30, 2022				1,878,060	1,878,060	473,113	(493,356)		(20,243)		1.857.817	(226,338)	1,631,479
Compensation cost arising from restricted shares of employees				1,070,000	1,070,000	4/3,113	(475,550)	39			39	(220,336)	39
Purchase and retirement of restricted shares of stock for employees	(360)	(6,198)	-	-	-	-	-	6,558		_	- 39	-	- 39
Changes in equity of associates accounted for using equity method	(300)	3,014	-	392	392	-	-	0,336	0,338	-	3,406	-	3,406
Stock option compensation cost of subsidiary	-	3,014	-	392	392	-	-	-	-	-	3,400	11,212	11,212
1 1	_	-	-	-	-	-	-	-	-	-	-	11,212	11,414
Disposal of investments in equity instruments designated at fair value through other comprehensive income	1			18.830	18,830		(18,830)		(18,830)				
	6 4 220 404	0.0((.720	3,892,688			202 704		·			33,407,459	1,968,862	35,376,321
Balance at September 30, 2022	\$ 4,239,404	9,966,730	3,872,088	14,573,048	18,465,736	203,704	531,885		735,589		33,407,459	1,900,802	35,3/0,321

WIN Semiconductors Corp. and Subsidiaries

Consolidated Statement of Cash Flows

For the nine months ended September 30, 2022 and 2021

(Expressed in Thousands of New Taiwan Dollars)

	For the	he nine months ende	ed September 30 2021
Cash flows from (used in) operating activities:	•	1.050.566	4.250.526
Profit before tax Adjustments:	\$	1,958,766	4,350,526
Adjustments to reconcile profit (loss):			
Depreciation expense		3,146,741	3,016,914
Amortization expense		107,305	98,613
Losses on expected credit impairment		704	125
Net losses (gains) on financial assets or liabilities at fair value through profit or loss Interest expense		715,883 246,561	(251,716) 223,839
Interest income		(42,905)	(27,478)
Dividend income		(205,733)	(37,260)
Share-based payments		11,251	55,343
Share of profit of associates and joint ventures accounted for using equity method		(259,255)	(60,512)
(Gains) losses on disposal of property, plant and equipment Prepayments for business facilities transferred to expenses		(36,001) 48	4,145 986
Changes in biological assets at fair value		(4,244)	(16,001)
Unrealized foreign exchange losses (gains)		614,269	(14,425)
Gains on repurchases of bonds payable		(360,101)	- '
Losses on lease modification		26,426	
Total adjustments to reconcile profit (loss)		3,960,949	2,992,573
Changes in operating assets and liabilities: Changes in operating assets:			
(Increase) decrease in financial assets at fair value through profit or loss		(543,880)	704,303
Decrease (increase) in notes and accounts receivable		1,404,629	(50,502)
Decrease (increase) in inventories		998,570	(1,259,730)
Decrease in biological assets		98,731	66,802
Decrease (increase) in other current assets		129,435	(96,985)
Total changes in operating assets Changes in operating liabilities:		2,087,485	(636,112)
Decrease in contract liabilities		(138,268)	(234,459)
(Decrease) increase in notes and accounts payable		(1,299,943)	424,792
Decrease in other payables		(877,637)	(97,341)
Increase in other current liabilities		44,709	33,930
Increase in other non-current liabilities		(2,270,790)	635 127,557
Total changes in operating liabilities Total changes in operating assets and liabilities	-	(183,305)	(508,555)
Cash inflow generated from operations		5,736,410	6,834,544
Dividends received		27,466	22,645
Income taxes paid		(1,375,915)	(1,604,934)
Net cash flows from operating activities		4,387,961	5,252,255
Cash flows from (used in) investing activities: Acquisition of financial assets at fair value through other comprehensive income		_	(2,744,229)
Proceeds from disposal of financial assets at fair value through other comprehensive income		19,744	297,557
Proceeds from capital reduction of financial assets at fair value through other comprehensive income		17,667	-
Acquisition of financial assets at fair value through profit or loss		(64,437)	(549,293)
Proceeds from disposal of financial assets at fair value through profit or loss		9,969	- 001
Proceeds from capital reduction of financial assets at fair value through profit or loss Acquisition of investments accounted for using equity method		8,719	901 (3,330,192)
Acquisition of property, plant and equipment		(4,568,332)	(4,840,630)
Proceeds from disposal of property, plant and equipment		80,743	5,072
Acquisition of intangible assets		(63,704)	(66,063)
Acquisition of right-of-use assets		(225.452)	(51,716)
Increase in other non-current assets Increase in prepayments for business facilities		(235,453) (1,639,575)	(14,011) (984,522)
Interest received		41,743	25,761
Dividends received		576,478	273,514
Net cash flows used in investing activities		(5,816,438)	(11,977,851)
Cash flows from (used in) financing activities:			40.000 ==4
Issuance of convertible bonds payable Increase in short-term loans		10 005	13,902,774
Proceeds from long-term debt		18,805 5,659,996	6,608,950
Repayments of long-term debt		(5,123,113)	(1,881,000)
Repayments of lease liabilities		(85,272)	(96,509)
(Decrease) increase in other non-current liabilities		(10,963)	12,048
Cash dividends paid		(3,391,811)	(4,240,414)
Interest paid		(84,774)	(66,007)
Changes in non-controlling interests Repurchases of bonds payable		(1 277 472)	695,982
Net cash flows (used in) from financing activities		(1,277,473) (4,294,605)	14,935,824
Effect of exchange rate changes on cash and cash equivalents		271,659	(84,536)
Net (decrease) increase in cash and cash equivalents		(5,451,423)	8,125,692
Cash and cash equivalents at beginning of period		16,331,759	8,356,270
Cash and cash equivalents at end of period	\$	10,880,336	16,481,962

WIN Semiconductors Corp. and Subsidiaries

Notes to the Consolidated Financial Statements September 30, 2022 and 2021

(Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(1) Company history:

WIN Semiconductors Corp. (the "Company") was incorporated on October 16, 1999 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The address of the Company's registered office is No. 69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan.

The main operations of the Company and its subsidiaries (together referred to as "the Group") are as follows:

- (a) Researching, developing, manufacturing, and selling of GaAs wafers.
- (b) Developing hog farming technology and trading.
- (c) Researching, manufacturing and selling of high-density gene chips, biochip optical readers, microelectrophoresis analyzers and diagnostic tool for endometrial cancer.

(2) Approval date and procedures of the consolidated financial statements:

These consolidated financial statements were reported for issuance by the Board of Directors as of November 11, 2022.

(3) New standards, amendments and interpretations adopted:

(a) The impact of the International Financial Reporting Standards ("IFRSs") endorsed by the Financial Supervisory Commission, R.O.C. ("FSC") which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2022:

- Amendments to IAS 16 "Property, Plant and Equipment—Proceeds before Intended Use"
- Amendments to IAS 37 "Onerous Contracts—Cost of Fulfilling a Contract"
- Annual Improvements to IFRS Standards 2018–2020
- Amendments to IFRS 3 "Reference to the Conceptual Framework"

(b) The impact of IFRS issued by the FSC but not yet effective

The Group assesses that the adoption of the following new amendments, effective for annual period beginning on January 1, 2023, would not have a significant impact on its consolidated financial statements:

- Amendments to IAS 1 "Disclosure of Accounting Policies"
- Amendments to IAS 8 "Definition of Accounting Estimates"
- Amendments to IAS 12 "Deferred Tax related to Assets and Liabilities arising from a Single Transaction"

(c) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or	Content of amendment	Effective date per IASB							
Interpretations									
Amendments to IAS 1	The amendments aim to promote	January 1, 2023							
"Classification of Liabilities	consistency in applying the requirements								
as Current or Non-current"	Surrent or Non-current" by helping companies determine whether,								
	in the statement of balance sheet, debt and								
	other liabilities with an uncertain								
	settlement date should be classified as								
	current (due or potentially due to be settled								
	within one year) or non-current.								
	•								
	The amendments include clarifying the								
	classification requirements for debt a								
	company might settle by converting it into								
	equity.								

The Group is evaluating the impact of its initial adoption of the abovementioned standards or interpretations on its consolidated financial position and consolidated financial performance. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture"
- IFRS 17 "Insurance Contracts" and amendments to IFRS 17 "Insurance Contracts"
- IFRS 16 "Requirements for Sale and Leaseback Transactions"

(4) Summary of significant accounting policies:

Except the following accounting policies mentioned below, the significant accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2021. For the related information, please refer to Note 4 of the consolidated financial statements for the year ended December 31, 2021.

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 "Interim Financial Reporting" which are endorsed by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed by the FSC (hereinafter referred to IFRS endorsed by the FSC) for a complete set of the annual consolidated financial statements.

(b) Basis of consolidation

(i) List of subsidiaries in the consolidated financial statements:

			September 30,	December 31,	September 30,	
Name of investor	Name of subsidiary	Principal activity	2022	2021	2021	Remark
The Company	WIN SEMI. USA, INC.	Marketing	100.00 %	100.00 %	100.00 %	
The Company	Win Semiconductors Cayman Islands Co., Ltd. (abbrev. Win Cayman)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Venture Capital Corp. (abbrev. WVC)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	Phalanx Biotech Group, Inc. (abbrev. PBL)	Researching, manufacturing and selling of high-density gene chips and testing service	73.67 %	73.67 %	81.68 %	(Note 1)
The Company	WIN Earn Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Chance Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
WVC	Phalanx Biotech Group, Inc.	Researching, manufacturing and selling of high-density gene chips and testing service	1.54 %	1.54 %	1.71 %	(Note 1)
Win Cayman	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. (abbrev. Chainwin Cayman)	Investment activities	81.23 %	81.23 %	81.23 %	
Chainwin Cayman	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Chance Agriculture Development Co., Ltd. (abbrev. Jiangsu Win Chance)	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Farm feed development and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Merit Runfu Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Yield Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	i-Chainwin Technology (Cayman Islands) Co., Ltd.	Investment activities	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Win Lux Biotech (Cayman Islands) Co., Ltd.	Investment activities	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Shine Agriculture Development Co., Ltd.	Logistics management service	100.00 %	100.00 %	100.00 %	

	Shareholding					
			September 30,	December 31,	September 30,	
Name of investor	Name of subsidiary	Principal activity	2022	2021	2021	Remark
Chainwin Cayman	i-Chainwin Technology Co., Ltd.	Information software services	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Win Lux Biotech Co., Ltd.	Biotechnology service and pharmaceutical testing	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Boutique Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Sunlight Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Honor Management Technology Co., Ltd.	Logistics management service	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Fortune Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Chainwin (Huaian) AloT Co., Ltd.	Information software services	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Advane Bio-Assay Co., Ltd.	Biotechnology testing service	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and bioassay	100.00 %	100.00 %	-	
Jiangsu Win Chance	Jiangsu Win Wonder Agriculture Development Co., Ltd.	Developing farming technology and trading	100.00 %	100.00 %	100.00 %	
PBL	PhalanxBio, Inc.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	
PBL	Phalanx Biotech Limited. (abbrev. PBL (HK))	Investment activities	100.00 %	100.00 %	100.00 %	
PBL	Guzip Biomarkers Corporation	Developing and selling of diagnostic tool for endometrial cancer	100.00 %	100.00 %	-	(Note 1)
PBL (HK)	Onearray Biotech (Kunshan) Co., Ltd.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	

Note 1: For the related information of the shareholding percentage change, please refer to notes 6(h) and 6(i) of the consolidated financial statements for the year ended December 31, 2021.

Note 2: The aforementioned subsidiaries were recognized based on the reviewed financial statements by the certified public accountant.

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

(c) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-time events.

(d) Income taxes

The income tax expenses have been evaluated and disclosed in accordance with paragraph B12 of IAS 34 "Interim Financial Reporting."

Income tax expenses for the period are best estimated by multiplying pre-tax income for the interim reporting period by the effective annual tax rate as forecasted by the management. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IFRSs (in accordance with IAS 34 "Interim Financial Reporting" and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Except for the following, the preparation of the consolidated financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2021. For the related information, please refer to Note 5 of the consolidated financial statements for the year ended December 31, 2021.

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements is as follows:

(a) Judgment of whether the Group has substantive control over its investee

The Group holds 49% of the outstanding voting shares of Rainbow Star Group Limited and is the single largest shareholder of the investee. The remaining 51% of Rainbow Star Group Limited's shares are concentrated within specific shareholders, and therefore the Group cannot obtain more than half of the total number of Rainbow Star Group Limited directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over Rainbow Star Group Limited.

The Group holds 20.80% of the outstanding voting shares of ITEQ Corporation (hereinafter referred to as "ITEQ") and is the single largest shareholder of the investee. Although the remaining 79.20% of ITEQ's shares are not concentrated within specific shareholders, the Group still cannot obtain more than half of the total number of ITEQ directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over ITEQ.

(b) Judgment of whether the Group has significant influence on its investee

The Group's 32.88% shares in NFC Fund II L.P. is deemed as a mutual fund. The Group does not act as the director and is not designed as the representative of those charged with the governance of NFC Fund II L.P. As a result, it is determined that the Group does not have significant influence on NFC Fund II L.P.

(6) Explanation of significant accounts:

Except for the following disclosure, the significant account disclosure in the consolidated financial statements for the nine months ended September 30, 2022, which compare with the consolidated financial statements for the year ended December 31, 2021, was not changed significantly. For the related information, please refer to Note 6 of the consolidated financial statements for the year ended December 31, 2021.

(a) Cash and cash equivalents

	Sept	tember 30, 2022	December 31, 2021	September 30, 2021
Cash on hand	\$	260	321	316
Cash in bank		9,715,576	13,647,220	11,227,864
Time deposits		1,164,500	2,684,218	5,253,782
	\$	10,880,336	16,331,759	16,481,962

Refer to Note 6(ab) for currency risk of the financial assets and liabilities and the fair value sensitivity analysis of the Group.

(b) Financial instruments

(i) Financial assets and liabilities at fair value through profit or loss:

	Se	ptember 30,	December 31,	September 30,
		2022	2021	2021
Mandatorily measured at financial assets at fair value through profit or loss:				
Non-derivative financial assets				
Publicly traded stocks (Note)	\$	290,366	18,541	13,809
Non-public stocks (Note)		-	380,417	292,219
Money market funds		587,762	43,334	42,218
Private fund (Note)		1,461,865	1,442,016	1,422,649
Total	\$	2,339,993	1,884,308	1,770,895
Current	\$	599,736	61,875	56,027
Non-current		1,740,257	1,822,433	1,714,868
	\$	2,339,993	1,884,308	1,770,895

Note: As of September 30, 2022, December 31 and September 30, 2021, part of the private fund, publicly traded stocks, and non-public stocks were during the lock-up period.

	Sep	otember 30, 2022	December 31, 2021	September 30, 2021
Mandatorily measured at current financial liabilities at fair value through profit or loss				
Convertible bonds with embedded derivatives	\$	597,050	180,497	244,860

The derivative financial instruments arose from the issuance of overseas convertible bonds of the Group disclosed in Note 6(q).

(ii) Non-current financial assets at fair value through other comprehensive income (FVOCI):

	September 30,		December 31,	September 30,
	2022		2022 2021	
Stocks listed on domestic markets	\$	69,299	124,844	96,013
Stocks listed on US markets		1,057,299	1,381,391	1,012,898
Non-public stocks		536,462	680,342	821,183
	\$	1,663,060	2,186,577	1,930,094

The Group decided to hold these equity instruments, which are not held for trading, at fair value through other comprehensive income.

For the three months and nine months ended September 30, 2022 and 2021, the group receives dividend income \$30,340 thousand, \$10,394 thousand, \$50,048 thousand and \$36,708 thousand, respectively, of the equity investment designated at fair value though other comprehensive income.

For the nine months ended September 30, 2022, due to the redemption of preferred shares, the Group disposed the financial assets at fair value through other comprehensive income, with a fair value of \$19,744 thousand; upon derecognition, the gains on disposal, accumulated in other equity, amounting to \$18,830 thousand was transferred to retained earnings.

For the nine months ended September 30, 2021, due to the proportion of investment portfolio, the Group disposed the equity investments designated at fair value through other comprehensive income, with a fair value of \$297,557 thousand; upon derecognition, the gains on disposal, accumulated in other equity, amounting to \$147,280 thousand was transferred to retained earnings.

As of July 2, 2021, due to operating strategy, the Group reclassified equity investments designated at fair value through other comprehensive income into investments accounted for using equity method. Please refer to Note 6(g) for related information.

(iii) Sensitivity analysis in the equity price risk:

If the equity price changes, the impact to comprehensive income, using the sensitivity analysis based on the same variables except for the price index for both periods, will be as follows:

	For the nine months ended September 30, 2022		For the nine months ended September 30, 2021		
Prices of securities at the reporting date	After-tax other comprehensive income	After-tax profit (loss)	After-tax other comprehensive income	After-tax profit (loss)	
Increasing 3%	\$ 49,892	8,711	57,903	9,181	
Decreasing 3%	\$(49,892)	(8,711)	(57,903)	(9,181)	

(iv) As of September 30, 2022, December 31 and September 30, 2021, the financial assets were not pledged. For information on the Group's credit risk and fair value information was disclosed in Note 6(ab).

(c) Notes and accounts receivable, net

	Sep	tember 30, 2022	December 31, 2021	September 30, 2021
Notes receivable	\$	830	1,053	1,039
Accounts receivable		1,312,997	2,717,312	2,087,076
Less: loss allowance		(1,601)	(805)	(236)
	\$	1,312,226	2,717,560	2,087,879

The Group applies the simplified approach to provide for its loss allowance used for expected credit losses, which permit the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivable have been grouped based on shared credit risk characteristics and days past due, as well as incorporate forward looking information.

The loss allowance provision was determined as follows:

(i) The segment of foundry and agriculture technology:

	September 30, 2022			
Not post due		ss carrying amount 1,168,468	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	Ф		0%	-
Past due 1~60 days		131,551		-
Past due 61~120 days		4,438	0%	-
Past due 121~180 days		-	0%~1.67%	-
Past due more than 181 days		699	100%	699
	\$	1,305,156		699
		D	ecember 31, 2021	
		ss carrying amount	ecember 31, 2021 Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due		ss carrying	Weighted- average expected loss	Lifetime expected credit
Not past due Past due 1~60 days	:	ss carrying amount	Weighted- average expected loss rate	Lifetime expected credit
•	:	ss carrying amount 2,556,855	Weighted- average expected loss rate	Lifetime expected credit
Past due 1~60 days	:	ss carrying amount 2,556,855	Weighted- average expected loss rate 0% 0%	Lifetime expected credit
Past due 1~60 days Past due 61~120 days	:	ss carrying amount 2,556,855	Weighted- average expected loss rate 0% 0% 0%	Lifetime expected credit

	September 30, 2021			
		oss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	2,007,658	0%	-
Past due 1~60 days		74,661	0%	-
Past due 61~120 days		-	0%	-
Past due 121~180 days		-	1.67%~5.00%	-
Past due more than 181 days			100%	
	\$	2,082,319		

(ii) The segment of gene chip testing service:

	September 30, 2022			
		ss carrying	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	6,995	0%~1.14%	6
Past due 1~60 days		814	0%~13.89%	97
Past due 61~120 days		26	0%~25%	6
Past due 121~180 days		86	0%~50%	43
Past due more than 181 days		750	100%	750
	\$	8,671		902
		D	ecember 31, 2021	<u> </u>
		ss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	4,927	0%~29.86%	23
Past due 1~60 days		1,060	0%~36.91%	10
Past due 61~120 days		27	0%~49.81%	-
Past due 121~180 days		11	0%~61.11%	6
Past due more than 181 days		766	100%	766
	\$	6,791		<u>805</u>

	September 30, 2021			
		s carrying mount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	4,859	0%~8.52%	11
Past due 1~60 days		122	0%~45.25%	21
Past due 61~120 days		49	0.18%~58.15%	-
Past due 121~180 days		766	26.65%~69.44%	204
Past due more than 181 days			100%	
	\$	5,796		236

The movements of loss allowance were as follows:

	mo	or the nine onths ended otember 30, 2022	For the nine months ended September 30, 2021
Beginning balance	\$	805	148
Impairment losses recognized		704	125
Amounts written off		-	(37)
Effect of changes in foreign exchange rates		92	
Ending balance	\$	1,601	236

As of September 30, 2022, December 31 and September 30, 2021, the notes and accounts receivable were not discounted nor pledged.

(d) Other receivables (recognized as other current assets)

	Sept	ember 30, 2022	December 31, 2021	September 30, 2021
Other receivables	\$	45,839	23,700	62,619
Less: loss allowance		-		
	\$	45,839	23,700	62,619

As of September 30, 2022, December 31 and September 30, 2021, other receivables were not past due nor impaired.

For information on the Group's credit risk was disclosed in Note 6(ab).

(e) Inventories

	September 30, 2022		December 31, 2021	September 30, 2021
Raw materials, supplies and spare parts	\$	4,327,762	4,352,874	4,144,310
Work in process		613,511	1,291,563	1,431,136
Finished goods		569,348	1,026,300	1,018,510
	\$	5,510,621	6,670,737	6,593,956

Except for cost of goods sold and inventories recognized as expenses, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	mo	r the three onths ended tember 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Losses on valuation of inventories and					
obsolescence	\$	13,127	1,715	204,888	66,610
Unallocated overheads	\$	75,625		163,830	
Revenue from sale of scraps	\$	(12,526)	(15,271)	(42,020)	(36,445)
Gains on physical inventory					
count	\$	(459)	(14)	(5,706)	(50)

As of September 30, 2022, December 31 and September 30, 2021, the inventories were not pledged.

(f) Biological assets

(i) List of biological assets:

	September 30, 2022		December 31, 2021	September 30, 2021	
Consumable biological assets	\$	54,016	138,494	119,813	
Bearer biological assets	\$	318,468	389,952	348,021	

(ii) Movements in biological assets:

	moi	r the nine of the	For the nine months ended September 30, 2021	
Beginning balance	\$	528,446	565,216	
Increase due to purchase		26,089	145,987	
Input costs		544,136	454,726	
Depreciation expenses		(75,296)	(39,588)	
Decrease due to sales and disposals		(668,956)	(667,515)	
Changes in fair value less costs to sell due to price changes		4,244	16,001	
Effect of changes in foreign exchange rates		13,821	(6,993)	
Ending balance	\$	372,484	467,834	
Current	\$	54,016	119,813	
Non-current		318,468	348,021	
	\$	372,484	467,834	

For the three months and nine months ended September 30, 2022 and 2021, the gains and losses of \$(8,853) thousand, \$(5,171) thousand, \$4,244 thousand and \$16,001 thousand, respectively, were recognized as operating costs of the consolidated statement of comprehensive income as a result of the remeasurement of biological assets at the higher of its carrying amount or fair value less costs to sell.

(iii) The numbers of the Group's biological assets were as follows:

Unit: head

	September 30,	December 31,	September 30,
	2022	2021	2021
Farrows, hogs and breeders	29,647	46,684	46,897

(iv) Fair value

There were no significant addition regarding the fair value of the Group's biological assets. For the related information, please refer to Note 6(f) of the consolidated financial statements for the year ended December 31, 2021.

(v) As of September 30, 2022, December 31 and September 30, 2021, the biological assets were not pledged.

(g) Investments accounted for using equity method

The components of investments accounted for using the equity method at the reporting date were as follows:

	September 30,	December 31,	September 30,	
	2022	2021	2021	
Associates	\$ 10,351,082	10,405,398	9,930,287	

(i) Associates

Associates which are material to the Group consisted of the followings:

		Main Operating Location/ Registered	Proportion of Shareholding and Voting Rights				
	Main Businesses and	Country of the		· · · · · · · · · · · · · · · · · · ·			
Name of Associates	Products	Company	2022	2021	2021		
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev. Jiangsu CM/Chainwin)	farming technology and	China	49 %	49 %	49 %		
ITEQ Corporation (abbrev. ITEQ)	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	Taiwan	20.80 %	20.80 %	20.21 %		

The fair value of significant associate listed on the Taiwan Stock Exchange Corporation (TWSE) which is material to the Group is as follows:

	Sept	ember 30,	December 31,	September 30,
		2022	2021	2021
ITEQ	\$	4,659,070	11,309,197	11,223,323

The Group has significant influence over ITEQ after acquiring two seats of the Board of Directors on July 2, 2021. Therefore, the original account under fair value through other comprehensive income financial assets amounting to \$7,275,063 thousand, was removed and reclassified into investment accounted for using equity method based on the fair value. The amount of profit related to the investment that was previously recognized in other comprehensive income of \$2,896,840 thousand that would not be reclassified to profit or loss was reclassified to retained earnings. In the second half of 2021, the Group subscribed 24,548 thousand shares of cash capital increase amounting to \$3,191,294 thousand and purchased 1,074 thousand shares amounting to \$138,898 thousand from open market. The amount of investment cost over net equity amounting to \$1,288,576 thousand was recognized as a deduction of retained earnings. Due to the aforementioned transactions, the shareholding percentage has increased from 15.55% to 20.21%. There was no such transaction for the nine months ended September 30, 2022.

The following consolidated financial information of significant associates has been adjusted according to individually prepared IFRS financial statements of these associates.

1) The financial information of Jiangsu CM/Chainwin:

		S	eptember 30, 2022	December 202		September 30, 2021
Current assets		\$	252,291	2.	31,717	242,515
Non-current assets			1,302,460	1,30	04,478	1,318,934
Current liabilities			(148,152)	(12	27,658)	(120,829)
Non-current liabilities	S	_	(31,953)	(31,592)	(30,961)
Net assets		\$_	1,374,646	1,3	76,945	1,409,659
	For the thre months ende September 30 2022	ed	For the three months ended September 30, 2021	For the months September 202	ended per 30,	For the nine months ended September 30, 2021
Operating revenue	\$ 139,8	<u>89</u>	19,742	3	<u> 394,825</u>	362,047
Profit (losses)	\$ 19,2	78	(48,065))	(43,109)	(172,651)
Other comprehensive income						
Total comprehensive income	\$ 19,2	<u>78</u>	(48,065)	<u>(43,109</u>)	(172,651)
				For the months Septemb	ended er 30,	For the nine months ended September 30, 2021
Carrying amount of eattributable to the G					573,302	785,949
Losses attributable to	•	0	8		(21,123)	ŕ
Exchange differences statements attribute	on translation		foreign financial		(69,354)	
Shares of net assets of		_	inwin at the end	<u> </u>	582,825	705,198
Add: Effect of change	C				89,144	(15,876)
Carrying amount of e attributable to the (quity of Jiangs	u C	•	\$	571,969	689,322

2) The financial information of ITEQ:

		S	September 30, 2022	December 31, 2021	September 30, 2021
Current assets		\$	20,641,664	24,375,370	25,131,170
Non-current assets			11,870,527	11,861,917	10,904,085
Current liabilities			(10,324,043)	(14,264,806)	(15,040,274)
Non-current liabilities	S		(2,190,616)	(657,743)	(640,519)
Net assets		\$	19,997,532	21,314,738	20,354,462
	mo	r the three nths ended tember 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Operating revenue	\$	6,352,008	8,929,775	22,266,721	24,493,890
Profit	\$	277,360	835,187	1,521,175	2,337,682
Other comprehensive income (loss)		164,939	(57,965)464,574	(216,169)
Total comprehensive income	\$	442,299	777,222	1,985,749	2,121,513
				For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Carrying amount of ed Group at the beginn		of ITEQ att	ributable to the	\$ 9,678,934	-
The fair value on the influence	date	of obtaining	significant	-	7,275,063
Additions				-	3,330,192
Profit attributable to t	he G	roup		286,544	145,986
Comprehensive incom	ne (lo	oss) attributa	ble to the Group	52,153	(17,690)
Deduction in retained capital increase	earn	ings from di	sproportionate	-	(1,288,596)
Dividend received fro	m as	sociates		(398,211	(258,899)
Changes in retained e	arnin	gs of associa	ates	392	-
Changes in capital sur	plus	of associate	S	3,014	1,137
Carrying amount of ea Group at the end	quity	of ITEQ att	ributable to the	9,622,826	9,187,193
Less: Goodwill				(5,245,224	(5,245,224)
Shares of net assets of	f ITE	Q at the end	l	\$ 4,377,602	

(Continued)

Summary of financial information for the individually insignificant investments in associates accounted for using equity method were as follows. The aforementioned financial information was included in the consolidated financial statements of the Group:

		Se	ptember 30, 2022	December 31, 2021	September 30, 2021	
Total equity of the indivinsignificant investment associates		•	56,287	53,162	53,772	
	mor	the three of the ended ember 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021	
Attributable to the Group:						
Losses	\$	(56,733)	(310	(6,166)	(875)	
Other comprehensive income				<u> </u>		
Total comprehensive income (loss)	\$	(56,733)	(310	(6,166)	(875)	

(ii) Pledge to secure

As of September 30, 2022, December 31 and September 30, 2021, the investments accounted for using equity method were not pledged.

(h) Changes in parent's ownership interest in a subsidiary

(i) Chainwin Cayman

On May 6, 2021, the Group subscribed the new shares contributed by Chainwin Cayman for \$2,764,000 thousand in cash. Therefore, in the second quarter of 2021, the Group decreased its ownership from 81.69% to 81.23%.

Based on the aforementioned transactions, the effects of the changes in shareholdings were as follows:

		or the nine onths ended
	Se	ptember 30, 2021
Carrying amount of interest on acquisition	\$	2,769,314
Consideration paid	_	(2,764,000)
Capital surplus changes in ownership interests in subsidiaries	\$ <u></u>	5,314

For the nine months ended September 30, 2022, there was no such transaction.

(ii) Phalanx Biotech

On July 8, 2021, the Group subscribed the new shares contributed by Phalanx Biotech for \$475,019 thousand in cash. Therefore, for the nine months ended September 30 2021, the Group increased its ownership from 58.87% to 83.39%.

Based on the aforementioned transactions, the effects of the changes in shareholding were as follows:

Carrying amount of interest on acquisition	mo	or the nine onths ended ptember 30,
Carrying amount of interest on acquisition	\$	448,015
Consideration paid		(475,019)
Capital surplus and retained earnings changes in ownership interests in subsidiaries	\$	(27,004)

For the nine months ended September 30, 2022, there was no such transaction.

(i) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

		Percentage of non-controlling interests				
		September 30,	December 31,	September 30,		
Subsidiaries	Registration	2022	2021	2021		
Chainwin Cayman	Cayman Islands	18.77 %	18.77 %	18.77 %		

The following information of the aforementioned subsidiaries have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers. Included in the information are the fair value adjustment made during the acquisition and relevant difference in accounting principles between the Group as at the acquisition date. Intergroup transactions were not eliminated in this information.

		Sep	tember 30, 2022	Dece	ember 31, 2021	September 30, 2021
Current assets		\$	3,570,090		4,842,182	5,532,471
Non-current assets			14,043,001		12,334,743	11,838,904
Current liabilities			(393,029)		(467,228)	(5,802,196)
Non-current liabilities			(7,544,451)		(5,974,406)	(493,406)
Net assets		\$	9,675,611		10,735,291	11,075,773
Non-controlling interests		\$	1,816,462		2,015,403	2,079,324
	For the the months en Septembe 2022	nded r 30,	For the three months ended September 30, 2021	l m	For the nine nonths ended eptember 30, 2022	For the nine months ended September 30, 2021
Operating revenue	\$ 9	2,075	60,24	8	288,648	340,741
Losses	\$ (51	4,173)	(269,62	22)	(1,468,560	(711,251)
Other comprehensive income (loss)	12	27,469	(9,65	<u>57</u>) _	408,880	(123,621)
Total comprehensive income (loss)	\$(38	<u>86,704</u>)	(279,27	<u>'9</u>) _	(1,059,680	(834,872)
Losses attributable to non- controlling interests	\$(9	<u>(6,529</u>)	(50,61	<u>8</u>) _	(275,702	(132,279)
Comprehensive income (loss), attributable to non-controlling interests		<u>(2,598</u>)	(52,43	<u>1</u>) _	(198,940	(154,592)
				m	For the nine nonths ended eptember 30, 2022	For the nine months ended September 30, 2021
Net cash flows used in operation	ng activities			\$	(972,494	(548,157)
Net cash flows used in investing	ng activities				(1,744,585	(3,336,823)
Net cash flows from financing	activities				658,110	5,305,533
Effect of changes in foreign ex	change rate			_	430,592	(2,995)
(Decrease) increase in cash an	d cash equiv	alents		\$ _	(1,628,377	1,417,558

(j) Property, plant and equipment

The movements in property, plant and equipment were as follows:

		Land	Buildings and structures	Machinery and equipment	Factory and equipment	Other equipment	Construction in progress and inspection- awaited devices	Total
Cost:								
Balance as of January 1, 2022	\$	2,546,534	5,409,451	20,272,516	6,406,045	565,461	9,402,246	44,602,253
Additions		-	335	510,587	211,996	106,868	3,675,955	4,505,741
Reclassification (Note 1)		-	(32,022)	1,573,227	18,162	45,172	480,648	2,085,187
Disposals		-	(108,968)	(3,458,899)	(597,241)	(38,336)	-	(4,203,444)
Effect of changes in foreign exchange rates	_	-	78,682	300	1,560	2,362	252,834	335,738
Balance as of September 30, 2022	\$_	2,546,534	5,347,478	18,897,731	6,040,522	681,527	13,811,683	47,325,475
Balance as of January 1, 2021	\$	2,546,534	2,445,758	22,097,218	6,180,047	642,560	6,706,796	40,618,913
Additions		-	24,209	330,078	278,317	113,600	4,140,244	4,886,448
Reclassification (Note 2)		-	541,067	832,750	247,466	(13,181)	(174,266)	1,433,836
Disposals		-	(70,463)	(2,682,387)	(138,454)	(169,887)	-	(3,061,191)
Effect of changes in foreign exchange rates	_	-	(1,150)	(142)	(773)	(910)	(129,396)	(132,371)
Balance as of September 30, 2021	\$_	2,546,534	2,939,421	20,577,517	6,566,603	572,182	10,543,378	43,745,635
Accumulated depreciation:							·	
Balance as of January 1, 2022	\$	-	1,045,218	12,327,474	3,213,613	231,951	-	16,818,256
Depreciation		-	194,879	2,235,026	424,708	124,072	-	2,978,685
Disposals		-	(108,941)	(3,415,461)	(595,964)	(38,336)	-	(4,158,702)
Effect of changes in foreign exchange rates	_	-	1,708	159	735	998		3,600
Balance as of September 30, 2022	\$_	_	1,132,864	11,147,198	3,043,092	318,685		15,641,839
Balance as of January 1, 2021	\$	-	921,015	12,894,424	3,019,553	361,704	-	17,196,696
Depreciation		-	110,579	2,238,614	402,729	133,503	-	2,885,425
Reclassification (Note 3)		-	73,108	(1)	-	(2,897)	-	70,210
Disposals		-	(68,757)	(2,680,986)	(132,344)	(169,887)	-	(3,051,974)
Effect of changes in foreign exchange rates	_	_	(319)	(88)	(382)	(447)		(1,236)
Balance as of September 30, 2021	\$_		1,035,626	12,451,963	3,289,556	321,976		17,099,121
Carrying amount:	_							
Balance as of January 1, 2022	\$_	2,546,534	4,364,233	7,945,042	3,192,432	333,510	9,402,246	27,783,997
Balance as of September 30, 2022	\$	2,546,534	4,214,614	7,750,533	2,997,430	362,842	13,811,683	31,683,636
Balance as of January 1, 2021	\$	2,546,534	1,524,743	9,202,794	3,160,494	280,856	6,706,796	23,422,217
Balance as of September 30, 2021	\$	2,546,534	1,903,795	8,125,554	3,277,047	250,206	10,543,378	26,646,514

Note 1: Inventories, prepayments for business facilities, capitalized right-of-use depreciation expenses and other current assets were reclassified as property, plant and equipment. Besides, property, plant and equipment were adjusted by using the construction refund.

Note 2: Inventories, prepayments for business facilities, investment property and capitalized right-of-use depreciation expenses were reclassified as property, plant and equipment.

Note 3: Investment property was reclassified as property, plant and equipment.

(i) Pledge to secure

As of September 30, 2022, December 31 and September 30, 2021, the property, plant and equipment were subject to a registered debenture to secured bank loans and line of credit, the collateral for these long-term borrowings was disclosed in Note 8.

(ii) Property, plant and equipment under construction

The Group rented some pieces of land and entered into different agreements for the construction of its new factories on the said lands. For the nine months ended September 30, 2022, the Group has constructed factories amounting to \$2,715,569 thousand, and has recognized as construction in progress. As of September 30, 2022, the total amount of the construction is \$11,308,072 thousand, and is recognized as construction in progress.

(iii) For the three months and nine months ended September 30, 2022 and 2021, capitalized interest expenses amounted to \$53,257 thousand, \$11,923 thousand, \$96,104 thousand and \$31,794 thousand, respectively. The annual interest rates at which these interest expenses were capitalized ranged from 0.9%~3.12%, 0.48%~0.65%, 0.57%~3.12% and 0.48%~0.72%, respectively.

(k) Right-of-use assets

The movements in right-of-use assets were as follows:

Cost:		Land	Buildings and structures	Other equipment	Total
Balance as of January 1, 2022	\$	986,869	482,647	20,853	1,490,369
Additions		67,209	83,812	638	151,659
Disposals		(137,947)	(94,419)	(964)	(233,330)
Effect of change in foreign exchange rates	_	13,317	1,804	104	15,225
Balance as of September 30, 2022	\$ _	929,448	473,844	20,631	1,423,923
Balance as of January 1, 2021	\$	530,419	393,559	13,630	937,608
Additions		525,773	114,505	12,829	653,107
Disposals		(10,003)	(23,320)	(5,928)	(39,251)
Effect of change in foreign exchange rates	_	(8,734)	(2,866)	<u>(17</u>)	(11,617)
Balance as of September 30, 2021	\$ _	1,037,455	481,878	20,514	1,539,847

Accumulated depreciation:	_	Land	Buildings and structures	Other equipment	Total
Balance as of January 1, 2022	\$	108,020	120,945	5,788	234,753
Depreciation (Note 1)	Ψ	42,265	41,927	4,627	88,819
Disposals		(29,377)	(42,375)	(964)	(72,716)
Effect of change in foreign exchange rates		1,755	205	11	1,971
Balance as of September 30, 2022	\$_	122,663	120,702	9,462	252,827
Balance as of January 1, 2021	\$	60,596	82,963	6,916	150,475
Depreciation (Note 2)		43,019	47,790	3,245	94,054
Disposals		(10,003)	(23,320)	(5,928)	(39,251)
Effect of change in foreign exchange rates	_	(880)	(2,457)		(3,337)
Balance as of September 30, 2021	\$_	92,732	104,976	4,233	201,941
Carrying amount:	_				
Balance as of January 1, 2022	\$_	878,849	361,702	15,065	1,255,616
Balance as of September 30, 2022	\$	806,785	353,142	11,169	1,171,096
Balance as of January 1, 2021	\$	469,823	310,596	6,714	787,133
Balance as of September 30, 2021	\$_	944,723	376,902	16,281	1,337,906

Note 1: Including capitalized depreciation expenses transferred to construction in progress, which amounted to \$46 thousand.

Note 2: Including capitalized depreciation expenses transferred to construction in progress, which amounted to \$6,140 thousand.

(l) Investment property

		Land	Buildings and structures	Total
Cost:				
Balance as of January 1, 2022	\$	963,127	138,225	1,101,352
Additions		-		
Balance as of September 30, 2022	<u>\$</u>	963,127	138,225	1,101,352
Balance as of January 1, 2021	\$	963,127	529,952	1,493,079
Additions		-	-	-
Reclassification as property, plant and equipment			(391,727)	(391,727)
Balance as of September 30, 2021	\$	963,127	138,225	1,101,352

	Land	Buildings and structures	Total
Accumulated depreciation:			
Balance as of January 1, 2022	\$ -	47,404	47,404
Depreciation	 _	3,987	3,987
Balance as of September 30, 2022	\$ -	51,391	51,391
Balance as of January 1, 2021	\$ -	112,298	112,298
Depreciation	-	3,987	3,987
Reclassification as property, plant and equipment	 	(70,210)	(70,210)
Balance as of September 30, 2021	\$ _	46,075	46,075
Carrying amount:			-
Balance as of January 1, 2022	\$ 963,127	90,821	1,053,948
Balance as of September 30, 2022	\$ 963,127	86,834	1,049,961
Balance as of January 1, 2021	\$ 963,127	417,654	1,380,781
Balance as of September 30, 2021	\$ 963,127	92,150	1,055,277
Fair value:			-
Balance as of January 1, 2022		\$_	1,183,495
Balance as of September 30, 2022		\$	1,166,666
Balance as of September 30, 2021		\$ <u></u>	1,193,014

When measuring the fair value of its investment property, the Group considered the present value of net cash flows to be generated from leasing the property. The expected net cash flows were discounted using the yield to reflect its specified inherit risk on the net cash flows. The inputs to the valuation technique used for measuring fair value were categorized as a Level 2 fair value. As of September 30, 2022, December 31 and September 30, 2021, the yield applied to the net annual rentals to determine fair value of property for which current prices in an active market were unavailable, was as follows:

	September 30,	December 31,	September 30,
Location	2022	2021	2021
Hsinchu	0.44%	0.42%	0.39%

As of September 30, 2022, December 31 and September 30, 2021, the investment properties were not pledged.

(m) Intangible assets

	Computer software and information systems	Goodwill	Others	Total
\$ 44,318	284,449	312,405	713	641,885
\$ 37,522	218,852	329,272	55	585,701
\$ 8,775	285,763	277,404	6,489	578,431
\$ 6,259	286,488	274,793	1,407	568,947
	\$ 37,522 \$ 8,775	Technical know-how software and information systems \$ 44,318 284,449 \$ 37,522 218,852 \$ 8,775 285,763	software and information systems Goodwill \$\begin{small} 44,318 & 284,449 & 312,405 \\ \$\begin{small} 37,522 & 218,852 & 329,272 \\ \$\begin{small} 8,775 & 285,763 & 277,404 \end{small}	software and information systems Goodwill Others \$ 44,318 284,449 312,405 713 \$ 37,522 218,852 329,272 55 \$ 8,775 285,763 277,404 6,489

There was no significant additions, disposals, or recognition and reversal of impairment losses of intangible assets for the nine months ended September 30, 2022 and 2021. As of September 30, 2022, amortization of intangible assets was disclosed in Note 12(a). Other information was disclosed in Note 6(n) of the consolidated financial statements for the year ended December 31, 2021.

As of September 30, 2022, December 31 and September 30, 2021, the intangible assets were not pledged.

(n) Other current assets and other non-current assets

	September 30, 1 2022		December 31, 2021	September 30, 2021	
Tax refund receivables	\$	123,892	125,031	103,806	
Other receivables		45,839	23,700	62,619	
Prepayments to suppliers		-	20,989	167,660	
Prepaid expenses		69,637	138,001	72,210	
Offset against business tax payable and input taxes		41,615	199,646	185,749	
Restricted assets		356,564	118,900	119,202	
Refundable deposits		149,717	160,040	170,498	
Long-term prepayments to suppliers		36,074	36,074	-	
Long-term prepaid intangible assets		1,808	2,672	53,472	
Others		26,746	38,225	41,369	
	\$	851,892	863,278	976,585	

(o) Short-term borrowings

	Sep	otember 30, 2022	December 31, 2021	September 30, 2021	
Secured short-term borrowings (in RMB)	\$	18,805			
Unused bank credit lines for short-term borrowings	\$	1,621,912	1,010,000	1,010,000	
Unused bank credit lines for short-term and long-term borrowings	\$	3,408,698	3,568,680	2,639,000	
Annual interest rate		3.75%			

The collateral for these short-term borrowings were disclosed in Note 8.

(p) Long-term borrowings

	S	September 30, 2022	December 31, 2021	September 30, 2021	
Secured long-term borrowings (in TWD)	\$	-	750,000	750,000	
Secured long-term syndicated borrowings (in USD)		7,211,956	5,522,160	5,549,112	
Unsecured long-term borrowings (in TWD)		10,190,747	9,720,660	9,770,340	
Less: Current portion	_	(989,227)		(5,549,112)	
Total	\$_	16,413,476	15,992,820	10,520,340	
Unused bank credit lines for long-term borrowings	\$ _	13,757,868	8,922,568	5,949,928	
Annual interest rate	=	0.75%~3.06%	0.25%~0.98%	0.25%~1.18%	
Expiry date	_2	2024/5/17~2029/1/20	2023/12/15~2025/8/16	2022/7/8~2025/8/16	

As of September 30, 2022, the remaining balances of the borrowing due were as follows:

Redemption period	Amount
October 1, 2022~September 30, 2023	\$ 989,227
October 1, 2023~September 30, 2024	3,617,680
October 1, 2024~September 30, 2025	12,139,546
October 1, 2025~September 30, 2026	187,500
October 1, 2026 and after	468,750
	\$ <u>17,402,703</u>

- (i) The unused bank credit lines for short-term and long-term borrowings at the reporting date were disclosed in Note 6(o).
- (ii) The collateral for these long-term borrowings were disclosed in Note 8.
- (iii) In June 2019, the Group entered into a three-year syndicated loan agreement with Far Eastern International Bank and other four banks. The total credit facility under this loan agreement is US\$200,000 thousand. The loan was repaid in April 2022.

The related financial covenants and restrictions for the syndicated loans mentioned above were as follows:

- 1) At the end of reporting period, current ratio (current assets / current liabilities): shall not be lower than 100%;
- 2) Interest coverage ratio [(profit before tax + depreciation + amortization + interest expense) / interest expense)]: shall not be lower than 100%; and
- 3) Tangible net assets value (equity intangible assets): shall not be lower than NT\$15,000,000 thousand.

After the guarantor signs the loan agreement, the aforementioned financial ratio and criteria will be reviewed semi-annually, which are based on the year-end consolidated financial statements audited by the Certified Public Accountants (CPAs) that are approved by the leading bank, as well as the semi-annual consolidated financial statements reviewed by the CPAs.

For the year ended December 31, 2021 and for the six months ended June 30, 2021, the Group were in compliance with the above financial covenants and restrictions.

(iv) In December 2021, the Group entered into a three-year syndicated loan agreement with Far Eastern International Bank and other ten banks. The total credit facility under this loan agreement is US\$300,000 thousand. The loans from the initial withdrawal should be first paid off the outstanding amount of syndicated loan agreement in June 2019.

The related financial covenants and restrictions for the syndicated loans mentioned above were as follows:

- 1) At the end of reporting period, current ratio (current assets / current liabilities): shall not lower than 100%;
- 2) Interest coverage ratio [(profit before tax + depreciation + amortization + interest expense) / interest expense)]: shall not be lower than 100%; and
- 3) Tangible net assets value (equity— intangible assets): shall not be lower than NT\$20,000,000 thousand.

After the guarantor signs the loan agreement, the aforementioned financial ratio and criteria will be reviewed semi-annually, which are based on the year-end consolidated financial statements audited by the Certified Public Accountants (CPAs) that are approved by the leading bank, as well as the semi-annual consolidated financial statements reviewed by the CPAs.

For the six months ended June 30, 2022 and for the year ended December 31, 2021, the Group were in compliance with the above financial covenants and restrictions.

(q) Bonds payable

The details of bonds payable were as follows:

	Sep	otember 30, 2022	December 31, 2021	Sep	otember 30, 2021
Overseas convertible bonds issuance balance	\$	12,284,976	13,992,000		13,992,000
Less: Unamortized discounted bonds payable		(506,603)	(705,361)		(747,876)
Current portion					
Total	\$	11,778,373	13,286,639	_	13,244,124
Proceeds from issuance (less transaction cost ar	noun	nted to \$89,226	thousand)	\$	13,902,774
Equity components (less transaction cost amort		(639,583)			
thousand)					
Embedded derivatives instruments—put/ call op	ption	S			(139,920)
Liability components at the issuance date (less	trans	action cost allo	ocated to liability		13,123,271
component of \$85,079 thousand)					
Interest expense at an effective interest rate of 1	.28%	6			290,343
Repurchases of bonds payable				_	(1,635,241)
Liability components at September 30, 2022				\$	11,778,373

The Company resolved to issue the first unsecured overseas convertible bonds, as proposed in the Board of Directors meeting held on November 27, 2020, which had been approved by the Financial Supervisory Commission with approval No.1090377907 on December 25, 2020 and been issued on the Singapore Exchange Securities Trading Limited on January 14, 2021. The Company issued the 5 years unsecured convertible bond, amounting to US\$500,000 thousand without coupon rate, with the maturity dates on January 14, 2026.

Unless previously redeemed, repurchased, and cancelled or converted, regulations and except during the closed period, the bonds may be converted into the Company's common shares pursuant to the applicable laws and regulations and the indenture at any time starting from the next day immediately after three months from the issue date to (1) the 10 day prior to the maturity date or (2) the 5 business day prior to the applicable redemption date on which a bondholder exercises its put right or the applicable date (other than the maturity date) on which the Company exercises its redemption right.

The conversion price was 140% of the closing price of the Company's common shares on the Taipei Exchange on the pricing date, which was NT\$497. The number of common shares to be delivered upon conversion of any bond will be determined with the principal amount of the bonds multiplied by the fixed exchange rate, which is NT\$27.984 to US\$1, which as determined on the pricing date and divided by the conversion price in effect on the date of conversion. After the issuance of the bonds, the conversion price shall be adjusted in accordance with the relevant anti-dilution provisions of the indenture. As of September 30, 2022, the conversion price was adjusted to NT\$464.04 per share.

The above-mentioned convertible bonds included liabilities and equity components. The equity component was accounted under the capital surplus-stock option. The effective interest rate originally recognized for the liability component was 1.28%.

For the nine months ended September 30, 2022, the Company has repurchased the first issued unsecured overseas convertible bonds in 2020 at the principle amount of US\$61,000 thousand, and consequently, derecognized the related derivative financial liabilities. The difference between the repurchased amount and the carrying amount was recognized under other gains and losses.

(r) Lease liabilities

The carrying amounts of lease liabilities were as follow:

	mber 30, 2022	December 31, 2021	September 30, 2021	
Current	\$ 113,276	122,882	132,042	
Non-current	\$ 976,907	1,034,327	1,078,223	

For the maturity analysis, please refer to Note 6(ab).

The amounts recognized in profit or loss were as follows:

	For the three months ended September 30, 2022		For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Interest expenses on lease liabilities	\$	6,526	6,381	20,191	17,028
Expenses relating to short-term leases	\$	1,147	1,515	4,711	7,627
Expenses relating to leases of low-value assets, excluding short-term leases of low-value assets	.	407	270	1 160	1 086
iow-value assets	\$	407	379	1,169	1,086

The amounts recognized in the statement of cash flows for the Group was as follows:

	For the nine	For the nine
	months ended	months ended
	September 30,	September 30,
	2022	2021
Total cash outflow for leases	\$112,471	114,528

(i) Real estate and buildings leases

The Group leases land and buildings and structures for its factories and staff dormitories. The leases of them typically run for a period of 2 to 50 years.

(ii) Other leases

The Group leases printer and transportation equipment, with lease terms of 2 to 10 years.

(iii) Others

Parts of the leases of transportation equipment, machinery and equipment, office and staff dormitories are with contract terms of less than one year. These leases are short-term. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases. Also, some leases contain cancellation options exercisable by the Group. In which lease is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(s) Operating lease

There were no significant changes in operating lease for the nine months ended September 30, 2022 and 2021. Please refer to Note 6(t) of the consolidated financial statements for the year ended December 31, 2021 for other related information.

(t) Employee benefits

(i) Defined benefit plans

At the end of the prior fiscal year, there was no material volatility of the market, no material reimbursement and settlement or other material one-time events. As a result, pension cost in the consolidated interim financial statements was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate as of December 31, 2021 and 2020.

The Group's expenses recognized in profit or loss were as follows:

	For the three months ended September 30, 2022		For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Operating costs	\$	-	-	-	-
Operating expenses		450	436	1,350	1,306
	\$	450	436	1,350	1,306

(ii) Defined contribution plans

The Group's expenses under the pension plan cost to the Bureau of Labor Insurance for the three months and nine months ended September 30, 2022 and 2021 were as follows:

	For the three months ended September 30, 2022		For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021	
Operating costs	\$	24,039	25,146	76,712	73,394	
Operating expenses		7,182	7,086	21,577	21,042	
	\$	31,221	32,232	98,289	94,436	

(iii) The Group's mainland China subsidiaries have a defined contribution plan. Monthly contributions to an independent fund administered by the government in accordance with the pension regulations in the People's Republic of China (PRC) are based on certain percentage of employees' monthly salaries and wages. Other than the monthly contributions, the Group has no further obligations. For the three months and nine months ended September 30, 2022 and 2021, the Group recognized the pension costs in accordance with the pension regulations and amounted to \$4,542 thousand, \$3,895 thousand, \$13,929 thousand and \$9,503 thousand, respectively.

(u) Income tax

(i) The amount of income tax expense was as follows:

	For the three	For the three	For the nine	For the nine
	months ended	months ended	months ended	months ended
	September 30,	September 30,	September 30,	September 30,
	2022	2021	2022	2021
Income tax expense	\$54,594	341,712	383,803	829,888

- (ii) There was no income tax expense recognized in other comprehensive income for the nine months ended September 30, 2022 and 2021.
- (iii) Assessment

The Company's corporate income tax returns for all the years through 2019 were assessed by the tax authorities.

(v) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the nine months ended September 30, 2022 and 2021. For the related information, please refer to Note 6(w) of the consolidated financial statements for the year ended December 31, 2021.

(i) Ordinary shares

On August 12, 2022, the Company's Board of Directors approved a resolution to redeem the unvested restricted employee share of stock 36 thousand shares, at \$10 dollars par value per share, amounting to \$360 thousand. The recognition date for capital reduction was August 31, 2022. All related registration had been completed.

On March 18, 2021, the Company's Board of Directors approved a resolution to redeem the unvested restricted employee share of stock 15 thousand shares, at \$10 dollars par value per share, amounting to \$150 thousand. The recognition date for capital reduction was March 31, 2021. All related registration procedures had been completed.

On December 22, 2017, the Company issued 20,000 thousand ordinary shares, with subscription price of \$277 per share, under private placement. The private placement of ordinary shares would be subject to section 43-8 requirements under the Securities and Exchange Act. The Company can only apply for these shares to be traded publicly after a three-year period has elapsed from the delivery date of the private placement securities, and after applying for a public offering with the Financial Supervisory Commission. The application of the aforementioned privately placed shares for public offering had been approved by the Competent Authorities. Therefore, the above shares took effect on June 23, 2021.

(ii) Capital surplus

Balance of capital surplus at the reporting date were as follows:

	September 2022		December 31, 2021	September 30, 2021	
Additional paid-in capital		9,234,813	9,190,855	9,190,855	
Equity component of convertible bonds		639,583	639,583	639,583	
Changes in ownership interests in subsidiaries		85,565	85,565	73,064	
Changes in equity of associates accounted for using the equity method		3,524	510	1,137	
Employee stock options		3,245	3,245	3,246	
Restricted shares of stock issued for employees	s	-	50,156	50,155	
	\$	9,966,730	9,969,914	9,958,040	

(iii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the balance of annual income or earnings after deducting accumulated deficit, if any, must be set aside as a legal reserve and a special capital reserve is likewise appropriated or the annual income or earnings are retained in accordance with the relevant laws or regulations or as requested by the authorities, but the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. Otherwise, the Company shall set aside at least 50% for shareholder, the distribution of remaining balance of the earnings should be further proposed by the Board of Directors and resolved by the shareholders' meeting. And the cash dividends should not lower than 10% of the total stockholders' dividends.

It is authorized the distributable dividends and bonuses or legal capital reserve and capital reserve in whole or in part may be paid in cash after a resolution has been adopted by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors; and in addition thereto a report of such distribution shall be submitted to the shareholders' meeting.

As the Company is a technology and capital-intensive enterprise and is in its growth phase, it has adopted a more prudent approach in appropriating its remaining earnings as its dividend policy in order to sustain its long-term capital needs and thereby maintain continuous development and steady growth.

The appropriations of earning for 2021 and 2020 had been approved in the meeting of Board of Directors held on March 18, 2021 and 2020, respectively. The appropriations and dividends were as follows:

	2021	2020
Cash dividends	\$ 3,391,811	4,240,414

The related information mentioned above can be found on websites such as the Market Observation Post System.

Unrealized

WIN Semiconductors Corp. and Subsidiaries Notes to the Consolidated Financial Statements

(iv) Other equity interests, net of tax

	diffe trai foreig	xchange erences on islation of gn financial atements	gains (losses) on financial assets at fair value through other comprehensive income	Other unearned compensation for restricted shares of employees
Balance as of January 1, 2022	\$	(269,409)	1,044,071	(6,597)
Foreign currency differences (net of tax):				
The Group		479,177	-	-
Associates		(6,064)	-	-
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax):				
The Group		-	(494,755)	-
Associates		-	1,399	-
Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax):			(18,830)	
Forfeiture of unvested restricted shares of employee		-	(10,030)	6,558
Compensation cost arising from restricted shares of		-	-	0,338
employees		_	_	39
Balance as of September 30, 2022	\$	203,704	531,885	
	diffe tran foreig sta	schange erences on aslation of gn financial atements	Unrealized gains (losses) on financial assets at fair value through other comprehensive income	Other unearned compensation for restricted shares of employees
Balance as of January 1, 2021	diffe tran foreig	schange erences on aslation of gn financial	gains (losses) on financial assets at fair value through other comprehensive	compensation for restricted shares of
Foreign currency differences (net of tax):	diffe tran foreig sta	echange erences on aslation of gn financial atements (202,205)	gains (losses) on financial assets at fair value through other comprehensive income	compensation for restricted shares of employees
Foreign currency differences (net of tax): The Group	diffe tran foreig sta	exchange erences on aslation of gn financial atements (202,205) (139,994)	gains (losses) on financial assets at fair value through other comprehensive income	compensation for restricted shares of employees
Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of	diffe tran foreig sta	echange erences on aslation of gn financial atements (202,205)	gains (losses) on financial assets at fair value through other comprehensive income	compensation for restricted shares of employees
Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax)	diffe tran foreig sta	exchange erences on aslation of gn financial atements (202,205) (139,994)	gains (losses) on financial assets at fair value through other comprehensive income	compensation for restricted shares of employees
Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax) Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other	diffe tran foreig sta	exchange erences on aslation of gn financial atements (202,205) (139,994)	gains (losses) on financial assets at fair value through other comprehensive income 3,780,846 40,243	compensation for restricted shares of employees
Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax) Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax)	diffe tran foreig sta	exchange erences on aslation of gn financial atements (202,205) (139,994)	gains (losses) on financial assets at fair value through other comprehensive income 3,780,846	compensation for restricted shares of employees (65,738)
Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax) Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other	diffe tran foreig sta	exchange erences on aslation of gn financial atements (202,205) (139,994)	gains (losses) on financial assets at fair value through other comprehensive income 3,780,846 40,243	compensation for restricted shares of employees (65,738)
Foreign currency differences (net of tax): The Group Associates Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax) Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax) Forfeiture of unvested restricted shares of employee Compensation cost arising from restricted shares of	diffe tran foreig sta	exchange erences on aslation of gn financial atements (202,205) (139,994)	gains (losses) on financial assets at fair value through other comprehensive income 3,780,846 40,243	compensation for restricted shares of employees (65,738)

(v) Treasury shares

On September 14, 2021, the Company took back unvested restricted employee share of stock amounting to 65 thousand shares, which should be cancelled in accordance with the regulations. As of September 30, 2021, there were 65 thousand shares amounting to \$650 thousand, which had not been cancelled and were recognized under treasury shares.

(w) Share-based payment

Except for the following disclosure, there were no significant changes for share-based payment for the nine months ended September 30, 2022 and 2021. For the related information, please refer to Note 6(x) of the consolidated financial statements for the year ended December 31, 2021.

(i) The Company issued restricted shares of stock (RSA) for employee

On May 13, 2022, the Company took back unvested restricted employee share of stock amounting to 36 thousand shares. In addition, on March 18, 2021, the Company resolved to redeem the unvested restricted employee share of stock amounting to 15 thousand shares. Furthermore, on September 14, 2021, the Company took back unvested restricted employee share of stock amounting to 65 thousand shares. For the nine months ended September 30, 2022 and 2021, 262 thousand and 1,048 thousand shares were vested, respectively. As of September 30, 2022 and 2021, there were 0 thousand and 1,310 thousand shares outstanding, respectively.

For the three months and nine months ended September 30, 2022 and 2021, the Company recognized the compensation cost of \$0 thousand, \$16,618 thousand, \$39 thousand and \$54,782 thousand for the aforementioned RSA, respectively.

(ii) The employee stock option (ESOPs) of subsidiary (PBL)

	2022 ESOPs
Grant date	2022.4.1
Number of options granted (unit)	6,440
Number of common shares eligible (share)	1,000
Contract period	2022.4.1~2030.3.31
Vesting period	2022.4.1~2025.3.31
Recipients	Employee of PBL

2022 ECOD

PBL used the Black-Scholes Model in measuring the fair value of its employee stock option at the date of grant. The main inputs to the valuation model were as follows:

	2022 employee stock options exercise in the 1st year	2022 employee stock options exercise in the 2nd year	2022 employee stock options exercise in the 3 rd year
Fair value at grant date (dollars)	\$ 5.29	\$ 5.37	\$ 5.51
Share price at grant date (dollars)	\$ 12.09	\$ 12.09	\$ 12.09
Exercise price (dollars)	\$ 10	\$ 10	\$ 10
Expected volatility	44.48%	42.90%	42.37%
Expected life	4.5 years	5 years	5.5 years
Risk-free interest rate	0.90%	0.91%	0.93%

Details of the employee stock options were as follows:

	For the nine months ended September 30, 2022		
	Weighted average exercise price (expressed in dollars)	Shares of options (expressed in thousands)	
Outstanding at January 1	\$ -	-	
Granted during the period	10	6,440	
Outstanding at September 30	10	6,440	
Exercisable at September 30	-	6,440	

For the three months and the nine months ended September 30, 2022 and 2021, the PBL recognized the compensation cost of \$5,638 thousand, \$0 thousand, \$11,212 thousand and \$561 thousand for the aforementioned ESOPs, respectively.

(x) Earnings per share ("EPS")

	For the three months ended September 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Basic earnings per share:				
Profit belonging to common shareholders	\$ 351,80	9 1,551,965	1,878,060	3,683,073
Weighted average number of outstanding shares of common stock	422.0	10 122 0/0	422.920	422 722
(in thousands shares)	423,94	=	423,830	422,732
Basic earnings per share (in dollars)	\$	3.67	4.43	8.71
Diluted earnings per share:				
Profit belonging to common shareholders	\$ 351,80	9 1,551,965	1,878,060	3,683,073
Interest expense and other gains and losses on convertible bonds, net of tax	(237,03	99,746		225,793
Profit belonging to common shareholders (diluted)	\$114,77	75 1,651,711	1,878,060	3,908,866

(Continued)

	For the three months ended September 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Weighted average number of outstanding shares of common stock (in thousands shares)	423,940	422,860	423,830	422,732
Effect of potentially dilutive common stock				
Employee remuneration (in thousands shares)	1,090	978	1,510	1,366
Restricted employee shares (in thousands shares)	-	1,137	110	1,275
Effect of conversion of convertible bonds (in thousands shares)	29,630	28,854		27,049
Weighted-average number of common stock (diluted) (in thousands shares)	454,660	453,829	425,450	452,422
Diluted earnings per share (in dollars)	\$ 0.25	3.64	4.41	8.64

For the nine months ended September 30, 2022, the convertible bonds have anti-diluted effects if the bonds were converted, and hence the convertible bonds were not included in the calculation of effect on potentially diluted common stock.

(y) Revenue from contracts with customers

(i) Disaggregation of revenue

	For the three months ended September 30, 2022				
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total
Primary geographical markets:					
Asia	\$	2,090,485	92,072	840	2,183,397
Americas		1,290,736	-	9,609	1,300,345
Taiwan		205,401	3	28,596	234,000
Europe	_	247,733		(56,733)	191,000
	\$_	3,834,355	92,075	(17,688)	3,908,742
Main product/ services lines:					
Foundry	\$	3,834,355	-	-	3,834,355
Others	_		92,075	(17,688)	74,387
	\$ _	3,834,355	92,075	(17,688)	3,908,742

		For the th	ree months end	led September 3	0, 2021
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total
Primary geographical markets:					
Asia	\$	4,127,893	60,248	(12,649)	4,175,492
Americas		1,945,052	-	7,485	1,952,537
Taiwan		328,284	-	38,802	367,086
Europe	_	266,852		(875)	265,977
	\$	6,668,081	60,248	32,763	6,761,092
Main product/ services lines:	-				
Foundry	\$	6,668,081	-	-	6,668,081
Others	_	-	60,248	32,763	93,011
	\$	6,668,081	60,248	32,763	6,761,092
		For the n	ine months end	ed September 30), 2022
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total
Primary geographical markets:	-	<u> </u>		(11000)	10111
Asia	\$	8,076,767	288,624	7,220	8,372,611
Americas		4,988,961	-	27,466	5,016,427
Taiwan		719,072	24	106,088	825,184
Europe	_	595,004		(6,166)	588,838
	\$	14,379,804	288,648	134,608	14,803,060
Main product/ services lines:	-				_
Foundry	\$	14,379,804	-	-	14,379,804
Others	_	-	288,648	134,608	423,256
	\$	14,379,804	288,648	134,608	14,803,060

735,408

WIN Semiconductors Corp. and Subsidiaries **Notes to the Consolidated Financial Statements**

Segment-Segment-Segment-Agriculture **Others Foundry** technology (Note) **Total** Primary geographical markets: 12,205,512 340,741 35,867 12,582,120 4,733,114 22,645 4,755,759 825,066 66,751 891,817

(875)

For the nine months ended September 30, 2021

340,741 18,499,975 124,388 18,965,104 Main product/ services lines: Foundry 18,499,975 18,499,975

736,283

profits and losses were recognized as operating revenue.

Others 340,741 124,388 465,129 18,499,975 340,741 124,388 18,965,104 Note: Segment-others were mainly general investment businesses, and their net investment

Balance of contracts (ii)

Asia

Americas

Taiwan

Europe

	Sep	tember 30, 2022	December 31, 2021	September 30, 2021	
Notes receivable	\$	830	1,053	1,039	
Accounts receivable		1,312,997	2,717,312	2,087,076	
Less: loss allowance		(1,601)	(805)	(236)	
	\$	1,312,226	2,717,560	2,087,879	
Contract liabilities	\$	214,889	353,157	299,967	

For details of notes and accounts receivable and allowance for impairment, please refer to Note 6(c).

The major change in the balance of contract liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received. The amount of revenue recognized for the nine months ended September 30, 2022 and 2021 that was included in the contract liabilities balance at the beginning of the period was \$298,485 thousand and \$501,073 thousand, respectively.

Employees' and directors' remuneration

According to the Company's Article of Incorporation, if there is any net profit after closing of a fiscal year, it shall be allocated according to the following principles:

Employees' remuneration: not less than 5% but no more than 10% and shall be determined and (i) pursuant to Employee Bonus Procedure of the Company. In addition, employee's profitsharing remuneration shall be distributed in the form of shares or cash. Stock-type employee remuneration may be distributed to qualified employees of affiliates of the Company.

(ii) Directors's remuneration: no more than 3%.

However, if there are any accumulated losses of the Company, the Company shall pre-reserve the amount to offset the loss. The distribution of employees' remuneration and directors's remuneration shall follow the special resolution by Board of Directors, and report it to the shareholders' meeting.

The Company estimated its employees' and directors' remuneration as follows:

	mo	or the three onths ended otember 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Employees' remuneration	\$	8,624	128,000	134,624	303,200
Directors' remuneration		7,000	37,200	43,000	88,000
	\$	15,624	165,200	177,624	391,200

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration, and multiplied by the rule of Company's Article of Incorporation. The above remuneration was included in the operating costs and operating expenses of for the three months and nine months ended September 30, 2022 and 2021. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

For the years ended December 31, 2021 and 2020, the Company accrued and recognized its employees' remuneration amounting to \$447,000 thousand and \$543,300 thousand, and directors' remuneration amounting to \$129,000 thousand and \$157,700 thousand, respectively. There were no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements. The related information mentioned above can be found on websites such as the Market Observation Post System.

(aa) Non-operating income and expenses

(i) Interest income

	mo	r the three nths ended tember 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021	
Interest income from bank deposits	\$	21,532	6,914	42,873	27,432	
Other interest income		9	9	32	46	
Interest income	\$	21,541	6,923	42,905	27,478	

(ii) Other income

` '		For the three months ended September 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Ι	Dividend income	\$ 25,651	2,910	178,267	14,615
F	Rent income	10,297	8,856	28,832	26,337
(Other income	\$ 35,948	11,766	207,099	40,952
(iii) (Other gains and losses				
		For the three months ended September 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
(Gains (losses) on disposals of property, plant and equipment	\$ 28,940	572	36,001	(4,145)
F	Foreign exchange gains (losses)	70,568	9,787	509,519	(147,423)
C	Gains (losses) on financial assets or liabilities at fair value through profit or loss	18,642	(2,122)	(560,799)	220,146
(Gains on repurchases of bonds payable	360,101	-	360,101	-
L	cosses on lease modification	(2,432)	-	(26,426)	-
C	Others	(2,190)	(17,465)	(40,294)	(15,288)
C	Other gains and losses	\$473,629	(9,228)	278,102	53,290

(iv) Finance costs

	mo	r the three nths ended tember 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Interest expenses					
Bank borrowings	\$	89,867	42,050	195,345	112,413
Bonds payable		41,536	42,379	126,975	120,853
Lease liabilities		6,526	8,283	20,237	22,256
Less: capitalized interest		(53,257)	(11,923)	(96,104)	(31,794)
Subtotal		84,672	80,789	246,453	223,728
Other finance costs		36	36	108	111
Finance costs	\$	84,708	80,825	246,561	223,839

(ab) Financial instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information, please refer to Note 6(ac) of the consolidated financial statements for the year ended December 31, 2021.

(i) Credit risk

1) Credit risk of receivables and debt securities

For information on credit risk regarding notes and accounts receivable, please refers to Note 6(c).

Other financial assets measured at amortized cost include other receivables. For related information of investment and impairment, please refers to Note 6(d).

All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited 12 months expected losses.

(ii) Liquidity risk

The following were the contractual maturities of financial liabilities:

	Carrying amount	Contractual cash flows	Within 1 year	1-2 years	2-5 years	Over 5 years
As of September 30, 2022						
Non-derivative financial liabilities						
Secured bank loans	\$ 7,230,761	8,089,214	242,718	223,749	7,622,747	-
Unsecured bank loans	10,190,747	10,420,340	1,092,628	3,695,147	5,348,699	283,866
Bonds payable	11,778,373	11,921,003	-	11,921,003	-	-
Notes and accounts payable	862,882	862,882	862,882	-	-	-
Other payables	2,504,875	2,504,875	2,504,875	-	-	-
Guarantee deposits received	119,435	119,435	169	119,266	-	-
Lease liabilities	1,090,183	1,331,800	124,899	112,273	293,209	801,419
	\$ 33,777,256	35,249,549	4,828,171	16,071,438	13,264,655	1,085,285
As of December 31, 2021						
Non-derivative financial liabilities						
Secured bank loans	\$ 6,272,160	6,420,797	40,043	189,481	6,191,273	-
Unsecured bank loans	9,720,660	9,864,259	60,610	2,659,255	7,144,394	-
Bonds payable	13,286,639	13,577,452	-	-	13,577,452	-
Notes and accounts payable	2,162,825	2,162,825	2,162,825	-	-	-
Other payables	3,440,833	3,440,833	3,440,833	-	-	-
Guarantee deposits received	130,398	130,398	11,951	8,447	110,000	-
Lease liabilities	1,157,209	1,429,386	134,132	119,574	300,119	875,561
	\$_36,170,724	37,025,950	5,850,394	2,976,757	27,323,238	875,561
As of September 30, 2021						
Non-derivative financial liabilities						
Secured bank loans	\$ 6,299,112	6,364,455	5,602,080	156,525	605,850	-
Unsecured bank loans	9,770,340	9,929,215	64,192	2,045,942	7,819,081	-
Bonds payable	13,244,124	13,577,452	-	-	13,577,452	-
Notes and accounts payable	2,219,460	2,219,460	2,219,460	-	-	-
Other payables	2,949,305	2,949,305	2,949,305	-	-	-
Guarantee deposits received	136,780	136,780	11,517	15,263	110,000	-
Lease liabilities	1,210,265	1,512,594	143,998	122,627	310,133	935,836
	\$ 35,829,386	36,689,261	10,990,552	2,340,357	22,422,516	935,836

The Group did not expect that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

(iii) Currency risk

1) Exposure to currency risk

The Group's significant exposure to foreign currency risk were as follows:

	Sep	tember 30, 202	2	December 31, 2021 Septe			otember 30, 20	21	
	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$
Financial assets									
Monetary items									
USD	\$ 300,452	31.75	9,539,356	453,406	27.68	12,550,289	499,536	27.85	13,912,085
EUR	1,051	31.26	32,846	57	31.32	1,775	1,291	32.32	41,729
ЈРҮ	956,530	0.2201	210,532	1,222,818	0.2405	294,088	1,064,956	0.2490	265,174
GBP	11	35.53	392	11	37.30	411	11	37.46	412
HKD	59	4.044	239	60	3.549	211	60	3.576	213
RMB	322	4.47	1,441	1,831	4.34	7,948	1,825	4.31	7,868
SGD	1	22.21	19	1	20.46	18	1	20.47	18
		\$	9,784,825		:	§ 12,854,740		:	§ 14,227,499
Non-monetary items									
USD	\$ 21,464	31.75	681,476	26,468	27.68	732,640	28,300	27.85	788,144
RMB	212,848	4.47	950,361	242,948	4.34	1,053,719	228,296	4.31	981,542
		\$	1,631,837		5	1,786,359		5	1,769,686
Financial liabilities									
Monetary items									
USD	\$ 209,415	31.75	6,648,922	233,251	27.68	6,456,379	233,881	27.85	6,513,588
EUR	180	31.26	5,631	641	31.32	20,086	371	32.32	12,005
JPY	374,954	0.2201	82,527	982,177	0.2405	236,214	890,368	0.2490	221,701
		\$	6,737,080		:	6,712,679		:	6,747,294

2) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, notes and accounts receivable, other receivables, financial assets at fair value through profit or loss, notes and accounts payable, other payables, long-term borrowings, etc. that are denominated in foreign currency. A strengthening (weakening) 5 % of appreciation (depreciation) of the TWD against the USD, EUR, GBP, JPY, HKD, RMB, SGD, etc. for the nine months ended September 30, 2022 and 2021 would have increased (decreased) the net profit after tax by \$149,169 thousand and \$330,732 thousand, respectively. The analysis assumes that all other variables remain constant.

3) Exchange gains or losses

Since the Group has many kinds of functional currency, the information on foreign exchange gains (losses) on monetary items is disclosed by total amount. For nine months ended September 30, 2022 and 2021, foreign exchange gains (losses) (including realized and unrealized portions) amounted to \$509,519 thousand and \$(147,423) thousand, respectively.

(iv) Interest rate risk

Please refer to the attached note for the liquidity risk and the Group's interest rate exposure to its financial liabilities.

The following sensitivity analysis is based on the risk exposure to interest rates on the nonderivatives financial instruments on the reporting date. For variable rate instruments, the sensitivity analysis assumes the variable rate liabilities are outstanding for the whole year on the reporting date.

If the interest rate increases (decreases) by 0.5%, the Group's net profit after tax would have increased (decreased) by \$45,936 thousand and \$39,833 thousand for the nine months ended September 30, 2022 and 2021, respectively, all other variable factors that remain constant. This is mainly due to the Group's borrowing in floating rates.

(v) Fair value

1) Financial instrument classifications and fair values

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income are measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities disclosure of fair value information is not required.

Funds and investment 587,762 587,762 − × × × × × × × × × × × × × × × × × × ×				Sept	tember 30, 2022		
Publicly traded stocks		Co	appring value	Level 1			Total
Prunds and investment 1,461,865 587,762 587,762 1,461,865 1,461,86	Financial assets at fair value through profit or loss		irrying value	Level 1	Level 2	Level 3	Total
Private fund	Publicly traded stocks	\$	290,366	290,366	-	-	290,366
Substate	Funds and investment		587,762	587,762	-	-	587,762
Financial assets at fair value through other comprehensive incomes State	Private fund		1,461,865	<u> </u>		1,461,865	1,461,865
Stocks listed on domestic and foreign markets \$ 1,126,598 1,126,598 . 536,462 536,46	Subtotal	\$	2,339,993	878,128	-	1,461,865	2,339,993
Non-public stocks	Financial assets at fair value through other comprehensive inco	me				_	
Subtotal	Stocks listed on domestic and foreign markets	\$	1,126,598	1,126,598	-	-	1,126,598
Financial assets measured at amortized cost	Non-public stocks		536,462		-	536,462	536,462
Cash and cash equivalents (Note) \$10,880,336	Subtotal	\$	1,663,060	1,126,598		536,462	1,663,060
Notes and accounts receivables (Note) 1,312,226 . . . Other receivables (Note) 45,839 . . . Subtoal \$ 12,744,682 . . . Financial liabilities at fair value through profit or loss Derivative financial liabilities measured at amortized cost Bank loans (Note) \$ 17,421,508 .	Financial assets measured at amortized cost						
Other receivables (Note) 45,839 (Other non-current assets (Note) 506,281 (Subtoal) -	Cash and cash equivalents (Note)	\$	10,880,336	-	-	-	-
Other non-current assets (Note) 506,281 - - - Subtotal \$ 12,744,682 - - - Financial liabilities at fair value through profit or loss 597,050 \$ 597,050 - \$ 597,050 Derivative financial liabilities measured at amortized cost 597,050 - \$ 597,050 - \$ 597,050 Bank loans (Note) \$ 17,421,508 - <	Notes and accounts receivable (Note)		1,312,226	-	-	-	-
Subtotal S 12,744,682	Other receivables (Note)		45,839	-	-	-	-
Primarcial liabilities at fair value through profit or loss S S97,050	Other non-current assets (Note)		506,281	-	-	-	-
Derivative financial liabilities S 597,050 - 597,050 - 597,050	Subtotal	\$	12,744,682				-
Derivative financial liabilities S 597,050 - 597,050 - 597,050	Financial liabilities at fair value through profit or loss						
Bank loans (Note)		\$	597,050	-	597,050	_	597,050
Bonds payable (Note)	Financial liabilities measured at amortized cost	=					
Bonds payable (Note)	Bank loans (Note)	\$	17,421,508	-	-	-	_
Notes and accounts payable (Note) 862,882 -				-	-	-	_
Other payables (Note) 2,504,875 -				-	-	-	-
Commendate deposits received (Note) 119,435				-	-	-	_
Carrying value Carr				-	-	-	_
Subtotal				-	-	-	-
Total Private fund Private fun	` '	<u> </u>					-
Carrying value Fair value							
Carrying value Level 1 Level 2 Level 3 Total		_		Dec		due	
Stocks listed on domestic markets \$ 18,541 18,541 - - 18,541 18,541 Non-public stocks 380,417 - - 380,417 380,417 Stocks and investment 43,334 43,334 - - 43,334 43,334 - - 1,442,016 1,442,016 Subtotal \$ 1,442,016 - - 1,442,016 1,442,016 1,442,016 Subtotal \$ 1,884,308 61,875 - 1,822,433 1,884,308 Stocks listed on domestic and foreign markets \$ 1,506,235 1,506,235 - - 1,506,235 Non-public stocks 680,342 - - 680,342 680,342 Subtotal \$ 2,186,577 1,506,235 - 680,342 2,186,577 Stocks and cash equivalents (Note) \$ 16,331,759 - - - - - - - - -		_Ca	rrying value	Level 1			Total
Non-public stocks 380,417 - - 380,417 Funds and investment 43,334 43,334 - - 43,334 Private fund 1,442,016 - - 1,442,016 1,442,016 Subtotal \$ 1,884,308 61,875 - 1,822,433 1,884,308 Financial assets at fair value through other comprehensive income - - 1,506,235 - - 1,506,235 Non-public stocks 680,342 - - - 680,342 680,342 Subtotal \$ 2,186,577 1,506,235 - 680,342 2,186,577 Financial assets measured at amortized cost -<	· .						
Funds and investment 43,334 43,334 43,334 Private fund 1,442,016 1,442,016 Subtotal \$ 1,884,308 61,875 - 1,822,433 1,884,308 Financial assets at fair value through other comprehensive income Stocks listed on domestic and foreign markets \$ 1,506,235 1,506,235 1,506,235 Non-public stocks 680,342 680,342 680,342 Subtotal \$ 2,186,577 1,506,235 - 680,342 2,186,577 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 16,331,759	Stocks listed on domestic markets	\$	18,541	18,541	-	-	18,541
Private fund 1,442,016 - - 1,442,016 1,442,016 Subtotal \$ 1,884,308 61,875 - 1,822,433 1,884,308 Financial assets at fair value through other comprehensive income Stocks listed on domestic and foreign markets \$ 1,506,235 - - - 1,506,235 Non-public stocks 680,342 - - - 680,342 680,342 Subtotal \$ 2,186,577 1,506,235 - 680,342 2,186,577 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 16,331,759 - - - - Notes and accounts receivable (Note) 2,717,560 - - - - Other receivables (Note) 23,700 - - - - Other non-current assets (Note) 278,940 - - - -	Non-public stocks		380,417	-	-	380,417	380,417
Subtotal \$ 1,884,308 61,875 - 1,822,433 1,884,308 Financial assets at fair value through other comprehensive income Stocks listed on domestic and foreign markets \$ 1,506,235 - - 1,506,235 Non-public stocks 680,342 - - 680,342 680,342 Subtotal \$ 2,186,577 1,506,235 - 680,342 2,186,577 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 16,331,759 - - - - - Notes and accounts receivable (Note) 2,717,560 - - - - - - - Other receivables (Note) 23,700 - <	Funds and investment		43,334	43,334	-	-	43,334
Financial assets at fair value through other comprehensive income Stocks listed on domestic and foreign markets \$ 1,506,235	Private fund		1,442,016			1,442,016	1,442,016
Stocks listed on domestic and foreign markets \$ 1,506,235 1,506,235 - - 1,506,235 Non-public stocks 680,342 - - 680,342 680,342 Subtotal \$ 2,186,577 1,506,235 - 680,342 2,186,577 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 16,331,759 - - - - - - Notes and accounts receivable (Note) 2,717,560 - <td>Subtotal</td> <td>\$</td> <td>1,884,308</td> <td>61,875</td> <td> _</td> <td>1,822,433</td> <td>1,884,308</td>	Subtotal	\$	1,884,308	61,875	 _	1,822,433	1,884,308
Non-public stocks 680,342 - - 680,342 680,342 Subtotal \$ 2,186,577 1,506,235 - 680,342 2,186,577 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 16,331,759 - - - - - - Notes and accounts receivable (Note) 2,717,560 - <td< td=""><td>Financial assets at fair value through other comprehensive inco</td><td>me</td><td></td><td></td><td></td><td></td><td></td></td<>	Financial assets at fair value through other comprehensive inco	me					
Subtotal \$ 2,186,577 1,506,235 - 680,342 2,186,577 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 16,331,759 -	Stocks listed on domestic and foreign markets	\$	1,506,235	1,506,235	-	-	1,506,235
Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 16,331,759	Non-public stocks		680,342			680,342	680,342
Cash and cash equivalents (Note) \$ 16,331,759 - - - - Notes and accounts receivable (Note) 2,717,560 - - - - Other receivables (Note) 23,700 - - - - Other non-current assets (Note) 278,940 - - - -	Subtotal	\$	2,186,577	1,506,235		680,342	2,186,577
Notes and accounts receivable (Note) 2,717,560 - - - - Other receivables (Note) 23,700 - - - - Other non-current assets (Note) 278,940 - - - -	Financial assets measured at amortized cost						
Other receivables (Note) 23,700 - - - - Other non-current assets (Note) 278,940 - - - - - -	Cash and cash equivalents (Note)	\$	16,331,759	-	-	-	-
Other non-current assets (Note) 278,940	Notes and accounts receivable (Note)		2,717,560	-	-	-	-
	Other receivables (Note)		23,700	-	-	-	-
Subtotal \$ 19,351,959	Other non-current assets (Note)	_	278,940	<u> </u>			-
	Subtotal	\$	19,351,959	<u> </u>	<u> </u>	<u> </u>	-

	December 31, 2021 Fair value						
	Ca	rrying value	Level 1	Level 2	Level 3	Total	
Financial liabilities at fair value through profit or loss							
Derivative financial liabilities	\$	180,497		180,497		180,497	
Financial liabilities measured at amortized cost							
Bank loans (Note)	\$	15,992,820	-	-	-	-	
Bonds payable (Note)		13,286,639	-	-	-	-	
Notes and accounts payable (Note)		2,162,825	-	-	-	-	
Other payables (Note)		3,440,833	-	-	-	-	
Guarantee deposits received (Note)		130,398	-	-	-	-	
Lease liabilities (Note)		1,157,209	<u> </u>	<u> </u>	<u> </u>	-	
Subtotal	\$	36,170,724	<u> </u>	<u> </u>		-	
			Sept	tember 30, 2021			
	Ca	rrying value	Level 1	Fair va	Level 3	Total	
Financial assets at fair value through profit or loss		irjing value		20,012	20,010	1000	
Stocks listed on domestic markets	\$	13,809	13,809	-	-	13,809	
Non-public stocks		292,219	-	-	292,219	292,219	
Funds and investment		42,218	42,218	-	-	42,218	
Private fund		1,422,649		<u> </u>	1,422,649	1,422,649	
Subtotal	s	1,770,895	56,027		1,714,868	1,770,895	
Financial assets at fair value through other comprehensive in	ncome						
Stocks listed on domestic and foreign markets	\$	1,108,911	1,108,911	-	-	1,108,911	
Non-public stocks		821,183	-	-	821,183	821,183	
Subtotal	\$	1,930,094	1,108,911	-	821,183	1,930,094	
Financial assets measured at amortized cost				: :=			
Cash and cash equivalents (Note)	\$	16,481,962	-	-	-	-	
Notes and accounts receivable (Note)		2,087,879	-	-	-	-	
Other receivables (Note)		62,619	-	-	-	-	
Other non-current assets (Note)		289,700	-	-	-	-	
Subtotal	\$	18,922,160	-	-	-	-	
Financial liabilities at fair value through profit or loss							
Derivative financial liabilities	\$	244,860	-	244,860	-	244,860	
Financial liabilities measured at amortized cost	=						
Bank loans (Note)	\$	16,069,452	-	-	-	-	
Bonds payable (Note)		13,244,124	-	-	-	_	
Notes and accounts payable (Note)		2,219,460	-	-	-	_	
Other payables (Note)		2,949,305	-	_	-	_	
Guarantee deposits received (Note)		136,780	-	-	-	_	
Lease liabilities (Note)		1,210,265	-	-	-	_	
Subtotal	s	35,829,386					
	_	,,,000					

Note: The information on fair value is not disclosed since the carrying amount is a reasonable approximation of fair value.

2) Valuation techniques of financial instrument not valued at fair value

The valuation techniques of the Group's financial instruments not valued at fair value by using the methods and assumptions are as follows:

• Financial assets measured at amortized cost and financial liabilities measured at amortized cost.

If recent transaction prices or market maker quotes are available, the fair value is based on such information. If there is no quoted market price available, the fair value is determined by using valuation techniques and calculated as the present value of the estimated cash flows.

- 3) Valuation techniques of financial instruments valued at fair value
 - a) Non-derivative instruments

The fair value of financial assets and liabilities traded in an active market is based on the quoted market prices. The quotation, which is published by the main exchange center or that which was deemed to be a public bond by the Treasury Bureau of Central Bank, is included in the fair value of the listed securities instruments and the debt instruments in active markets with open bid.

A financial instrument is regarded as the quoted price in an active market if the quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency; and if those prices represent the actual and regularly occurring market transactions on an arm's length basis. Otherwise, the market is deemed to be inactive. Normally, a market is considered to be inactive when:

- The bid-ask spread is increasing; or
- The bid-ask spread varies significantly; or
- There has been a significant decline in trading volume.

When the financial instrument of the Group is traded in an active market, its fair value is illustrated by the category and nature as follows:

- Financial assets and liabilities with standard terms and conditions and traded in an active market, for example, investment in stock of listed companies: the fair value is based on the market quoted price.
- Close-end funds with standard terms and conditions, such as money market funds; investors can require the investment trust company to redeem the fund at any time. The fair value is based on the net value of the fund.

Except for the above-mentioned financial instruments traded in an active market, the fair value is based on the valuation techniques or the quotation from the counter-party. The fair value refers to the current fair value of the other financial instruments with similar conditions and characteristics, using a discounted cash flow analysis or other valuation techniques, such as calculations of using models (for example, applicable yield curve from Taipei Exchange, or average quoted price on interest rate of commercial paper from Reuters), based on the information acquired from the market at the balance sheet date.

When the financial instrument of the Group is not traded in an active market, its fair value is determined as follows:

- The fair value is determined based on the ratio of the quoted market price of the comparative listed company and its book value per share and its sales revenue per share. Also, the fair value is discounted for its lack of liquidity in the market.
- The fair value is determined by using the asset-based approach, whose assumptions are based on the market approach, income approach, cost approach or other valuation methods according to the nature of the assets or liabilities of the subject companies.

b) Derivative instruments

The fair value is determined by using the models that are acceptable to the market participants, for example, discounted cash flow analyses or option pricing models. Forward exchange contracts are measured using quoted forward exchange rates. The fair value of structured interest derivative financial instruments is determined by using the proper option pricing models, such as Black-Scholes model, or other valuation technique, such as Monte Carlo simulation.

4) Level transfers of financial instruments

In April 2022, Vanchip (Tianjin) Technology Co, Ltd., which the Group holds an investment in equity shares of, listed its equity shares on a stock exchange and they are currently actively traded in the market. Because the equity shares now have published price quotation in an active market, the fair value measurement was transferred from Level 3 to Level 1 of the fair value hierarchy since the second quarter of 2022. For the nine months ended September 30, 2021, there was no transfer of financial instrument.

5) Movement of level 3

	Fa	ir value throug	h profit or loss	Fair value through other comprehensive income
		Unquoted		Unquoted
		equity	D	equity
D. 1		nstruments_	Private fund	instruments
Balance as of January 1, 2022	\$	380,417	1,442,016	680,342
Total gains or losses:				
Recognized in profit and loss		4,927	(35,869)	-
Recognized in other comprehensive income		-	-	(110,539)
Purchased		-	64,437	-
Disposals		-	-	(19,744)
Capital reduction		-	(8,719)	(17,667)
Transfers out of level 3		(398,433)	-	-
Effect of changes in foreign exchange rates		13,089		4,070
Balance as of September 30, 2022	\$		1,461,865	536,462
Balance as of January 1, 2021	\$	-	814,065	963,298
Total gains or losses:				
Recognized in profit and loss		30,848	321,516	-
Recognized in other comprehensive income		-	-	(153,485)
Purchased		261,324	287,969	12,000
Capital reduction		-	(901)	-
Effect of changes in foreign exchange rates		47		(630)
Balance as of September 30, 2021	\$	292,219	1,422,649	821,183

The preceding gains and losses were recognized as "other gains and losses" and "unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income". As of September 30, 2022 and 2021, the related information of the assets which were still held by the Group were as follows:

	mon Septe	the three ths ended ember 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Total gains or losses					
Profit or loss (recognized as other gains and losses) Other comprehensive income (recognized as unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive	\$	(166,183)	49,786	(35,869)	352,364
income)		(65,422)	(71,008)	(110,539)	(153,485) (Continued)

6) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include "financial assets at fair value through profit or loss — equity investment", "financial assets at fair value through profit or loss — private funds" and "financial assets at fair value through other comprehensive income — equity investments."

Most of the fair value measurements categorized within Level 3 use the single and significant unobservable input. Equity investments without an active market contains multiple significant unobservable inputs. The significant unobservable inputs of the equity investments are independent from each other, as a result, there is no relevance between them.

Quantified information of significant unobservable inputs was as follows:

Item Financial assets at fair value through other comprehensive income – equity investments without an active market	Valuation technique ● Comparable listed companies approach	Significant unobservable inputs Price-book ratio (as of September 30, 2022, December 31 and September 30, 2021 were 1.66~4.76, 1.66~6.27 and 1.60~6.83, respectively) Market liquidity discount rate (as of	Inter-relationships between significant unobservable inputs and fair value measurement The higher the price-book ratio, the higher the fair value The higher the market liquidity discount rate,
an active market		September 30, 2022, December 31 and September 30, 2021 were all 20%)	the lower the fair value
	Net asset value method	Net asset value	• The higher the net assets value, the higher the fair value
Financial assets at fair value through profit or loss – equity investments without an active market	Comparable listed companies approach	• Price-to-sale ratio (as of December 31 and September 30, 2021 were 5.97 and 5.67, respectively.)	• The higher the price-to sales ratio, the higher the fair value
		 Market liquidity discount rate (as of December 31 and September 30, 2021 were both 20%) 	 The higher the market liquidity discount rate, the lower the fair value
Financial assets at fair value through profit or loss – private fund	Net asset value method	Net asset value	• The higher the net assets value, the higher the fair value

7) Sensitivity analysis of reasonably possible alternative assumptions for fair value measurements in Level 3 of the fair value hierarchy

The fair value measurements of the Group's financial instruments are reasonable. However, changes in the use of valuation models or valuation variables may affect the estimations. For fair value measurements in Level 3, a fluctuation in the valuation variable by 5% would have the following effect:

]		anges in fair rofit or loss	Effects of changes in fair value on other comprehensive income		
	Inputs	Increase or decrease		Favorable_	<u>Unfavorable</u>	Favorable	Unfavorable	
September 30, 2022								
Financial assets at fair value through profit or loss								
Private fund	Net asset value	5%	\$	73,093	(73,093)	-	-	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%		-	-	8,605	(8,605)	
"	Market liquidity discount rate	5%		-	-	8,605	(8,605)	
<i>II</i>	Net asset value	5%		-	-	18,219	(18,219)	
December 31, 2021								
Financial assets at fair value through profit or loss								
Equity investments without an active market	Price-to-sales ratio	5%	\$	19,021	(19,021)	-	-	
"	Market liquidity discount rate	5%		19,021	(19,021)	-	-	
Private fund	Net asset value	5%		72,101	(72,101)	-	-	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%		-	-	13,944	(13,944)	
"	Market liquidity discount rate	5%		-	-	13,944	(13,944)	
<i>"</i>	Net asset value	5%		-	-	20,073	(20,073)	
September 30, 2021								
Financial assets at fair value through profit or loss								
Equity investments without an active market	Price-to-sales ratio	5%	\$	14,611	(14,611)	-	-	
"	Market liquidity discount rate	5%		14,611	(14,611)	-	-	
Private fund	Net asset value	5%		71,132	(71,132)	-	-	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%		-	-	19,121	(19,121)	
"	Market liquidity discount rate	5%		-	-	19,121	(19,121)	
"	Net asset value	5%		-	-	21,938	(21,938)	

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the inter-relationships with another input.

(ac) Management of financial risk

There was no significant change in the Group's objective and policies for the management of financial risk of the consolidated financial statements for the nine months ended September 30, 2022 which compared with the consolidated financial statements Note 6(ad) for the year ended December 31, 2021.

(ad) Capital management

The Group's objective, policies and process of capital management of the consolidated financial statements for the nine months ended September 30, 2022 was the same as the consolidated financial statements for the year ended December 31, 2021. For the related information, please refer to Note 6(ae) of the consolidated financial statements for the year ended December 31, 2021.

As of September 30, 2022, December 31 and September 30, 2021, the Group's return on common equity was 7.33%, 15.81% and 14.69%, respectively. The Group's debt ratio at the reporting date were as follows:

	September 30,	December 31,	September 30,	
	2022	2021	2021	
Debt ratio	49.75 %	50.43 %	51.42 %	

(ae) Financing activity

Reconciliations of liabilities arising from financing activities were as follows:

			Cash flows			Non-cash changes			
	January 1, 2022	Proceeds from long- term debt and bonds payable	Repayments of long-term debt and lease liabilities	Others	Interest expense	Others	Amortization of arranger fee of syndicated loan	September 30, 2022	
Short-term borrowings	\$ -	18,805	-	-	-	-	-	18,805	
Long-term borrowings	15,992,820	5,659,996	(5,123,113)	-	-	846,551	26,449	17,402,703	
Bonds payable	13,286,639	-	(1,247,799)	-	126,975	(387,442)	-	11,778,373	
Guarantee deposit received	130,398	-	-	(10,963)	-	-	-	119,435	
Lease liabilities (Note 1)	1,157,209		(85,272)	(21,319)	20,237	19,328		1,090,183	
Total liabilities from financing activity	\$ 30,567,066	5,678,801	(6,456,184)	(32,282)	147,212	478,437	26,449	30,409,499	

				Cash flows			Non-cash changes			
	Jar	nuary 1, 2021	Proceeds from long- term debt and bonds payable	Repayments of long-term debt and lease liabilities	Others	Interest expense	Others	Amortization of arranger fee of syndicated loan	September 30, 2021	
Long-term borrowings	\$	11,418,620	6,608,950	(1,881,000)	-	-	(98,169)	21,051	16,069,452	
Bonds payable		-	13,902,774	-	-	120,853	(779,503)	-	13,244,124	
Guarantee deposit received		124,732	-	-	12,048	-	-	-	136,780	
Lease liabilities (Note 2)	_	699,884		(96,509)	(9,306)	22,256	593,940		1,210,265	
Total liabilities from financing activity	\$_	12,243,236	20,511,724	(1,977,509)	2,742	143,109	(283,732)	21,051	30,660,621	

Note 1: Interest expense includes capitalized interest expense transferred to construction in progress, which amounted to \$46 thousand.

Note 2: Interest expense includes capitalized interest expense transferred to construction in progress, which amounted to \$5,228 thousand.

(7) Related-party transactions:

(a) Names and relationship with related parties

The followings are entities that have had transactions with related party during the periods covered in the consolidated financial statements:

Name of related party	Relationship with the Group
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev.	Associates
Jiangsu CM/Chainwin)	
ITEQ Corporation (abbrev. ITEQ) (Note)	Associates
Chainwin i-Management (Huaian) Co., Ltd.	Other related parties
Taoyuan i-Fare Charity Foundation	Other related parties

Note: In July 2021, the Group has significant influence over ITEQ, and therefore the ITEQ has become the Group's associates since July 2021.

(b) Significant transactions with related parties

(i) Purchases

The amounts of significant purchases by the Group from related parties were as follows:

	For the three	For the three	For the nine	For the nine	
	months ended	months ended	months ended	months ended	
	September 30,	September 30,	September 30,	September 30,	
	2022	2021	2022	2021	
Other related parties	\$	2,536		6,255	

The terms and pricing of purchase transactions with related parties were not significantly different from those offered by other vendors.

(ii) Operating expenses

The amounts of operating expenses by the Group from related parties were as follows:

	For the three	For the three	For the nine	For the nine
	months ended	months ended	months ended	months ended
	September 30,	September 30,	September 30,	September 30,
	2022	2021	2022	2021
Other related parties	<u> </u>			4,000

(iii) Guarantee

As of September 30, 2022, December 31, and September 30, 2021, Chainwin Cayman had provided a guarantee for loans amounting to US\$7,350 thousand (\$233,363 thousand, \$203,448 thousand and \$204,698 thousand, respectively) to its associate, Jiangsu CM/Chainwin.

(iv) Property transactions—acquire assets

Account	Category	mon Septe	ths ended	For the nine months ended September 30, 2022	
Property, plant	Other related parties				
and equipment		\$	-	 	654

(v) Leases

The Group leased the office and factories to its associate, ITEQ, and the rent income received monthly is based on the nearby office and factories rental rates. The amount of rent income is \$7,375 thousand, \$7,231 thousand, \$22,127 thousand and \$21,694 thousand for the three months and nine months ended September 30, 2022 and 2021. The preceding rent payment has been received. The guarantee deposits received amounted to \$110,000 thousand as of September 30, 2022, December 31, and September 30, 2021.

(c) Transactions with key management personnel

Key management personnel compensation was comprised as below:

	m	or the three onths ended ptember 30, 2022	For the three months ended September 30, 2021	For the nine months ended September 30, 2022	For the nine months ended September 30, 2021
Short-term employee benefits	\$	41,286	141,449	233,139	484,872
Post-employment benefits	_	315	314	945	943
	\$ _	41,601	141,763	234,084	485,815

(8) Pledged assets:

The carrying amounts of pledged assets were as follows:

Pledged assets	Pledged to secure	Sep	otember 30, 2022	December 31, 2021	September 30, 2021
Other non-current assets	Land, plant, and dormitory lease guarantee	\$	36,733	35,043	35,063
Other non-current assets	Bank borrowings		219,131	9,310	9,368
Other non-current assets	Gas deposits		4,700	4,700	4,700
Other non-current assets	Customs guarantee with interest		20,786	20,579	20,579
Other non-current assets	Guarantee deposits of letters of credit		-	44,056	44,325
Other non-current assets	Seized funds and court security deposits		75,214	5,212	5,167
Property, plant and	Bank borrowings				
equipment		_	2,177,104	2,244,061	2,266,358
Total		\$	2,533,668	2,362,961	2,385,560

(9) Commitments and contingencies:

(a) Contingencies: None.

(b) Commitment:

(i) The unrecognized commitment of acquisition of plant expansion and machinery equipment was as follows:

Sentember 30.

December 31.

		2022	2021	2021
	The unrecognized amount	\$ 6,756,46	7,431,148	6,622,161
(ii)	The unused letters of credit was a	s follows:		
		September 30, 2022	December 31, 2021	September 30, 2021
	The unused letters of credit	\$ 4,58	4 43,956	20,145

Sentember 30.

(10) Losses due to major disasters: None.

(11) Subsequent events: None.

(12) Other:

(a) The followings were the summary statement of employee benefits, depreciation and amortization expenses by function:

	For the three i	nonths ended S 2022	eptember 30,	For the three i	nonths ended S 2021	eptember 30,
	as operating as operating Total as operating as		Classified as operating expenses	Total		
Employee benefits						
Salaries	462,785	220,396	683,181	764,939	362,308	1,127,247
Labor and health insurance	59,818	21,209	81,027	62,217	21,033	83,250
Pension	25,520	10,693	36,213	26,229	10,334	36,563
Director remuneration	-	7,030	7,030	-	37,200	37,200
Others	25,620	7,126	32,746	35,257	14,553	49,810
Depreciation	849,835	188,008	1,037,843	906,319	83,398	989,717
Amortization	8,256	26,677	34,933	9,011	23,948	32,959

	For the nine n	nonths ended Se 2022	eptember 30,	For the nine n	nonths ended Se 2021	eptember 30,
	Classified as operating costs	Classified as operating expenses	Total	Classified as operating costs	Classified as operating expenses	Total
Employee benefits						
Salaries	1,861,427	818,905	2,680,332	2,214,177	1,028,015	3,242,192
Labor and health insurance	195,740	62,003	257,743	179,971	58,445	238,416
Pension	81,100	32,468	113,568	75,841	29,404	105,245
Director remuneration	-	43,117	43,117	-	88,116	88,116
Others	84,434	22,839	107,273	108,649	44,510	153,159
Depreciation	2,685,169	461,572	3,146,741	2,727,918	288,996	3,016,914
Amortization	24,789	82,516	107,305	26,244	72,369	98,613

(b) Seasonality of operations:

The Group's operations were not affected by seasonality or cyclicality factors.

(13) Other disclosures:

(a) Information on significant transactions:

The following were the information on significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the Group for the nine months ended September 30, 2022:

- (i) Loans to other parties: Please refer to schedule A.
- (ii) Guarantees and endorsements for other parties: Please refer to schedule B.
- (iii) Securities held as of September 30, 2022 (excluding investment in subsidiaries, associates and joint ventures): Please refer to schedule C.
- (iv) Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule D.
- (v) Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule E.
- (vi) Information on disposal of real estate with amounts exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: None.
- (vii) Information regarding related-parties purchases and/or sales with amounts exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: Please refer to schedule F.
- (viii) Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: Please refer to schedule G.
- (ix) Information regarding trading in derivative financial instruments: Please refer to Note 6(b).
- (x) Business relationships and significant intercompany transactions: Please refer to schedule H.
- (b) Information on investments: Please refer to schedule I.
- (c) Information on investment in mainland China: Please refer to schedule J.
- (d) Information on major shareholders: Please refer to schedule K.

(14) Segment information:

- (a) The Group's reportable segment is the foundry segment, and agriculture technology segment. The segment engages separately in researching, developing, manufacturing, selling of GaAs wafers and developing hog farming technology and trading, etc., respectively.
 - Other operating segments are mainly engaged in investment activities and gene chip and testing, which do not exceed the quantitative thresholds to be reported.
- (b) Operating segment profit or loss (includes reportable segment revenue and expenses), segment assets, segment liabilities, and their measurement and reconciliations for the three months and nine months ended September 30, 2022 and 2021, the reportable amount is same as that in the report used by the operating decision maker and the operating segment accounting policies are same as the ones described in Note 4 "significant accounting policies" were as follows:

For the three months ended September 30, 202. Revenue:	2	Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
Revenue from external customers	\$	3,834,355	92,075	(17,688)	_	3,908,742
Interest expenses	\$	46,970	36,091	1,647		84,708
Depreciation and amortization	\$	973,138	91,052	8,586		1,072,776
Share of profit (loss) of associates and joint ventures accounted for using equity method Reportable segment profit or loss	\$_ \$_	43,912	9,447 (164,839)	(47,176) (241,556)	<u>-</u>	6,183
Assets:	-					
Capital expenditures in noncurrent assets	\$_	1,263,326	650,538	4,566		1,918,430
For the three months ended September 30, 202 Revenue:	<u>1</u> _	Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
	1 \$_	Foundry 6,668,081	0		and	Total6,761,092
Revenue:			technology	Others	and	
Revenue: Revenue from external customers		6,668,081	technology 60,248	Others 32,763	and	6,761,092
Revenue: Revenue from external customers Interest expenses		6,668,081 53,576	60,248 25,536	Others 32,763 1,713	and elimination	6,761,092 80,825
Revenue: Revenue from external customers Interest expenses Depreciation and amortization Share of profit (loss) of associates and joint ventures accounted for using equity method	\$_ \$_ \$_ \$_	6,668,081 53,576 969,703 123,036	60,248 25,536 46,671 (23,552)	Others 32,763 1,713 5,981 22,640	and elimination	6,761,092 80,825 1,022,676

For the nine months ended September 30, 2022 Revenue:	Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
Revenue from external customers	\$ 14,379,804	288,648	134,608	_	14,803,060
Interest expenses	\$ 146,557	95,007	4,997		246,561
Depreciation and amortization	\$ 2,960,966	267,866	25,214		3,254,046
Shares of profit (loss) of associates and joint ventures accounted for using equity method	\$ 235,333	(21,123)	45,045		259,255
Reportable segment profit or loss	\$ <u>2,370,678</u>	(689,534)	(218,133)		1,463,011
Assets:					
Capital expenditures in noncurrent assets	\$ <u>4,831,075</u>	1,432,467	8,069		6,271,611
For the nine months ended September 30, 2021 Revenue:	Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
	Foundry \$ 18,499,975			and	Total
Revenue:		technology	Others	and	
Revenue : Revenue from external customers	\$ 18,499,975	<u>technology</u> <u>340,741</u>	Others 124,388	and	18,965,104
Revenue: Revenue from external customers Interest expenses	\$ <u>18,499,975</u> \$ <u>149,303</u>	340,741 69,351	Others 124,388 5,185	and elimination	18,965,104 223,839
Revenue: Revenue from external customers Interest expenses Depreciation and amortization Shares of profit (loss) of associates and joint	\$ <u>18,499,975</u> \$ <u>149,303</u> \$ <u>2,976,682</u>	340,741 69,351 116,760	Others 124,388 5,185 19,829	and elimination	18,965,104 223,839 3,115,527
Revenue: Revenue from external customers Interest expenses Depreciation and amortization Shares of profit (loss) of associates and joint ventures accounted for using equity method	\$\frac{18,499,975}{\$\frac{149,303}{\$\frac{2,976,682}{\$}\}\$	340,741 69,351 116,760 (84,599)	Others 124,388 5,185 19,829 22,075	and elimination	18,965,104 223,839 3,115,527 60,512

For the three months and nine months ended September 30, 2022 and 2021, reportable segment profit or loss excludes non-operating income and expenses, amounting to \$499,769 thousand, \$28,120 thousand, \$495,755 thousand and \$(63,682) thousand, respectively.

Schedule A Loans to other parties:

(In thousands of Dolla

Number (Note 1)	Name of lender	Name of borrower	Account name	Related party	Highest balance of financing to other parties during the period (Note 2)	Ending balance (Note 2)	Actual amount drawn down	mount Interest rate f		Purposes of fund financing for the borrower amount (Note 3)		Allowance for bad debts	Collateral Item Value		Individual funding loan limits (Note 4) (Note 5)	Maximum limit of fund financing (Note 4) (Note 5)	Remark
1	Chainwin Biotech and Agrotech	Jiangsu Chainwin Kang Yuan	Other receivables	Y	1,111,250	635,000	158,750	1%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 7)
	(Cayman Islands) Co., Ltd.	Agricultural Development Co., Ltd.			(USD 35,000	(USD 20,000	(USD 5,000)				Capital				1,935,122	3,870,244	
1	Chainwin Biotech and Agrotech	Jiangsu Win Yield Agriculture	Other receivables	Y	635,000	635,000	476,250	1%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 7)
	(Cayman Islands) Co., Ltd.	Development Co., Ltd.			(USD 20,000	(USD 20,000	(USD 15,000)				Capital				1,935,122	3,870,244	
2	Phalanx Biotech Group, Inc.	PhalanxBio, Inc.	Other receivables	Y	318	318	-	4%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 7)
					(USD 10	(USD 10					Capital				116,120	232,241	

Note 1: Company numbering as follows:

Issuer - 0

Investee starts from 1

Note 2: The credit amount to lending.

Note 3: Purposes of lending were as follows:

1. Business relationship

2. Short-term financing

Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of financing to other parties:

- 1. The loan limit to an individual party:(1) the total amount for lending to a company having business relationship with Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).
- (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s equity based on its most recent audited or reviewed financial statements by a certified accountant.
- 2. The maximum loans to other parties limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.
- Note 5: Phalanx Biotech Group, Inc.'s operating procedures of financing to other parties:
 - 1. The loan limit to an individual party: (1) the total amount for lending to a company having business relationship with Phalanx Biotech Group, Inc. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).
 - (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Phalanx Biotech Group, Inc.'s equity based on its most recent audited or reviewed financial statements by a certified accountant.
 - 2. The maximum loans to other parties provided by Phalanx Biotech Group, Inc. should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.
- Note 6: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to TWD for TWD 31.75.
- Note 7: The amount of the transaction had been offset in the consolidated financial statements.

Schedule B Guarantees and endorsements for other parties:

(ln	thousands	of	Dol	lars	١
---	----	-----------	----	-----	------	---

		Counter-party of guarantee and endorser	ment									(ands of Bonars)
Number (Note 1)	Name of guarantor	Name	Relationship with the Company (Note 2)	Limitation on amount of guarantees and endorsements for a specific enterprise (Note 3)(Note 4)	Highest balance of guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 3)(Note 4)	Parent company endorsements/ guarantees to subsidiary (Note 6)	Subsidiary endorsements/ guarantees to parent company (Note 6)	Endorsements/ guarantees to the companies in mainland China (Note 6)
0	The Company	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	2	16,703,729	2,645,823	2,328,323	1,270,000	-	6.97%	Net equity 50%= 16,703,729	Y	-	-
0	"	Jiangsu Chainwin Kang Yuan Agricultural	2	16,703,729	3,598,323	1,693,323	1,905,000	-	5.07%	Net equity 50%=	Y	-	Y
0	"	Development Co., Ltd. Jiangsu Win Yield Agriculture Development Co., Ltd.	2	16,703,729	5,185,854	2,328,354	2,857,500	-	6.97%	16,703,729 Net equity 50%= 16,703,729	Y	-	Y
0	"	Jiangsu Win Shine Agriculture Development Co., Ltd.	2	16,703,729	-	-	-	-	0.00%	Net equity 50%= 16,703,729	Y	-	Y
0	//	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	2	16,703,729	2,328,323	1,058,323	1,270,000	-	3.17%	Net equity 50%= 16,703,729	Y	-	Y
0	"	Jiangsu Win Chance Agriculture Development Co., Ltd.	2	16,703,729	-	-	-	-	0.00%	Net equity 50%= 16,703,729	Y	-	Y
0	"	Jiangsu Win Fortune Agrichture Development Co., Ltd.	2	16,703,729	846,677	846,677	-	-	2.53%	Net equity 50%= 16,703,729	Y	-	Y
0	"	Jiangsu Win Boutique Agriculture Development Co. Ltd.	2	16,703,729	635,000	635,000	-	-	1.90%	Net equity 50%= 16,703,729	Y	-	Y
0	"	Jiangsu Win Sunlight Agriculture Development Co. Ltd.	2	16,703,729	635,000	635,000	-	-	1.90%	Net equity 50%= 16,703,729	Y	-	Y
1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu CM/Chainwin Agriculture Development Co., Ltd.	6	2,902,683 (USD 91,423)	233,363 (USD 7,350)	233,363 (USD 7,350)	-	-	2.41%	Net equity 50%= 4,873,805	-	-	Y
1	"	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	2	2,902,683 (USD 91,423)	142,875 (USD 4,500)	142,875 (USD 4,500)	18,805 (RMB 4,204)	158,750 (USD 5,000)	1.48%	Net equity 50%= 4,873,805	-	-	Y

Note 1: Company numbering as follows:

- 1. Issuer 0
- 2. Investee starts from 1

Note 2: The 7 types of relationship between the guarantee and the guaranter were as follows:

- 1. For entities the guarantor has business transaction with.
- 2. For entities in which the guarantor, directly or indirectly, owned more than 50% of their shares.
- 3. For entities who owned, directly or indirectly, more than 50% in total of the guarantor's shares.
- 4. For entities in which the guarantor, directly or indirectly, owned more than 90% of their shares.
- 5. Fulfillment of contractual obligation by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
- 6. For entities who are guaranteed and endorsed by all capital contributing shareholders in proportion to each of their shareholder's percentage.
- 7. Performance guarantee in which entities within the same industry provide among themselves joint and several securities by entering into sales agreement with each other for pre-construction project pursuant to Company Protection Act.
- Note 3: WIN Semiconductors Corp.'s operating procedures of guarantee and endorsement were as follows:
 - 1. The guarantees and endorsements limit provided by WIN Semiconductors Corp. to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 2. The guarantees and endorsements limit provided by WIN Semiconductors Corp. and its subsidiaries to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 3.WIN Semiconductors Corp. endorses and guarantees the bank debts of its subsidiaries, including Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd., Jiangsu Win Yield Agriculture Development Co., Ltd., Jiangsu Win Fortune Agriculture Development Co., Ltd., Jiangsu Win Fortune Agriculture Development Co., Ltd., Jiangsu Win Fortune Agriculture Development Co., Ltd., Jiangsu Win Sullight Agriculture Development Co., Ltd. Jiangsu Win Sullight Agriculture Development Co., Ltd. The total amount of the endorsement guarantee should not exceed US\$300,000 thousand until the end of the month, and the balance of the endorsement guarantee should not exceed US\$300,000 thousand at the end of the period.
- Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of guarantee and endorsement were as follows:
 - 1. The individual guarantee amount should not exceed 30% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 2. The guarantees and endorsements limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
- Note 5: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to TWD and RMB to USD for TWD 31.75 and USD 0.1409, respectively.
- Note 6: Fill in "Y" for those cases of provision of endorsements/ guarantees by listed parent company to subsidiary, provision by subsidiary to listed parent company, and provision to the party in mainland China.

Schedule C Securities held as of September 30, 2022 (excluding investment in subsidiaries, associates and joint ventures):

(In thousands of New Taiwan Dollars)

	Category and Relationship					balance		Τ
Name of holder	Category and name of security	With the company	Account title	Shares/ Units (in thousands)	Carrying value	Percentage of ownership (%)	Fair value	Remark
The Company	Lin BioScience, Inc./Stock	None	Current financial assets at fair value through profit or loss	55	11,974	0.08	11,974	
WIN Venture Capital Corp.	Capital Money Market Fund	"	n n	17,781	290,661	-	290,661	
WIN Chance Investment Corp.	Capital Money Market Fund	"	"	15,540	254,028	-	254,028	
WIN Earn Investment Corp.	Capital Money Market Fund	"	n .	2,635	43,073	-	43,073	
					599,736		599,736	
The Company	MagiCapital Fund II L.P.	"	Non-current financial assets at fair value through profit or loss	-	418,385	5.81	418,385	1
II.	CDIB Capital Growth Partners L.P.	"	ıı .	-	158,835	3.30	158,835	
II.	CDIB Capital Healthcare Ventures II L.P.	"	"	-	27,953	1.61	27,953	
II.	Fuh Hwa Oriental Fund	"	"	15,000	28,920	-	28,920	
II.	Fuh Hwa Smart Energy Fund	"	<i>II</i>	12,000	87,264	-	87,264	
II.	LeaSun Winion L.P.	"	"	-	29,100	12.47	29,100	
"	NFC Fund II L.P.	"	"	-	263,091	32.88	263,091	
II.	Foryou Venture Capital L.P.	"	<i>II</i>	-	29,100	5.77	29,100	
II.	Renaissance Capital Limited Partnership	"	"	-	111,269	12.82	111,269	
"	Lian Ding Capital Investments Limited Partnership	"	"	-	210,000	10.23	210,000	
"	NFC Fund III, L.P.	"	"	-	97,948	19.90	97,948	
Win Semiconductors Cayman Islands Co., Ltd.	Vanchip (Tianjin) Technology Co., Ltd./Stock	Client	"	1,800	278,392	0.45	278,392	
·					1,740,257		1,740,257	
The Company	Sino-American Silicon Products Inc./Stock	None	Non-current financial assets at fair value through other comprehensive income	529	69,299	0.09	69,299	
<i>II</i>	Inventec Solar Energy Corporation/Stock	"	"	34,000	-	10.51	-	(Note 1)
"	CDIB Capital Creative Industries Limited/Stock	"	n/	3,000	20,250	3.33	20,250	
"	MagiCap Venture Capital Co., Ltd./Preferred Stock A	"	n,	543	45,842	18.28	45,842	
"	New Future Capital Co., Ltd./Stock	"	n/	8,900	90,780	15.87	90,780	
II .	Grand Fortune Venture Corp./Stock	"	"	4,000	47,280	6.87	47,280	
II.	NFC I Renewable Power Co., Ltd./Stock	"	<i>II</i>	16,200	160,218	15.00	160,218	
"	Gogolook Co., Ltd./Stock	"	n,	3,550	120,707	11.83	120,707	
Win Semiconductors Cayman Islands Co., Ltd.	Broadcom Ltd./Stock	Client	n/	75	1,057,299	0.02	1,057,299	
"	Anokiwave Inc./Series B Preferred Stock	"	n,	1,264	11,468	7.93	11,468	
WIN Venture Capital Corp.	MOAI Green Power Corporation/Stock	None	n/	90	-	0.24	-	
	Merit Biotech INC./Stock	"	"	1,320	-	2.93	-	(Note 2)
"	Winresp INC./Stock	"	n/	2,740	39,917	13.40	39,917	
				[1,663,060		1,663,060]
								1

Note 1: The Board of Directors of Inventec Solar Energy Corporation had declared to bankruptcy the company in December 2021. As of September 30, 2022, the company was still within the period of liquidation. Note 2: The Board of Directors of Merit Biotech INC. had resolved to dissolve and liquidate the company in 2017. As of September 30, 2022, the company was still within the period of liquidation.

Schedule D Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

	Category and			Relationship	Beginr	ning	Purchases				Sales		End	Jing
Name of Company	name of security	Account name	Name of counter-party	with the Company	Shares (in thousands)	Amount	Shares (in thousands)	Amount	Shares (in thousands)	Price	Cost	Gain (loss) on disposal	Shares (in thousands)	Amount
Chainwin Biotech and Agrotech	Jiangsu Chainwin Kang Yuan	Investments accounted for using equity method	-	Subsidiary	-	3,167,667	-	560,600	-	-	-	-	-	2,347,896
(Cayman Islands) Co., Ltd.	Agricultural Development Co., Ltd.													(Note 1)
"	Jiangsu Win Yield Agriculture	"	-	"	-	1,932,345	-	361,790	-	-	-	-	-	1,976,945
	Development Co., Ltd.													(Note 1)

Note 1: The amount of ending balance was calculated using the equity method. The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

Schedule E Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital:

(In thousands of Dollars)

Name of			Transaction			Relationship	If the counter-party is a rela disclose the previous transfer				References for	Purpose of	
Company	Name of Property	Transaction Date	amount	Status of payment	Counter-party	with the Company	Owner	Relationship with the Company	Date of transfer	Amount	determining price	acquisition	Others
The Company	Factory buildings	2021/4/6~2021/5/25	1,517,330	As of September 30, 2022, the price paid \$947,789 thousand.	Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None
И	Factory buildings	2021/10/15	2,324,768	As of September 30, 2022, the price paid \$1,081,146 thousand.	Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None
N.	Factory buildings	2022/6/9	525,000	As of September 30, 2022, the price paid \$157,500 thousand.	Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None
Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Factory buildings	2020/12/23		As of September 30, 2022, the price paid \$1,465,107 thousand (RMB 327,503 thousand).	Jiangsu Huaitian Construction Ltd.	-	N/A	N/A	N/A	N/A	Price comparison and price negotiation	Operating purpose	None
Jiangsu Win Yield Agriculture Development Co., Ltd.	Factory buildings	2020/1/10		As of September 30, 2022, the price paid \$1,462,859 thousand (RMB 327,000 thousand).	Jiangsu Nantong Sanjian Construction Group Co., Ltd.	-	N/A	N/A	N/A	N/A	Price comparison and price negotiation	Operating purpose	None
"	Factory buildings	2020/12/8	1,174,319 (RMB 268,600)	As of September 30, 2022, the price paid \$1,201,602 thousand (RMB 268,600 thousand).	Jiangsu Huaitian Construction Ltd.	-	N/A	N/A	N/A	N/A	Price comparison and price negotiation	Operating purpose	None
n n	Factory buildings	2021/2/8	548,075 (RMB 125,000)	As of September 30, 2022, the price paid \$599,197 thousand (RMB 125,000 thousand).	Jiangsu Huaitian Construction Ltd.	-	N/A	N/A	N/A	N/A	Price comparison and price negotiation	Operating purpose	None
"	Factory buildings	2021/5/12~2021/8/25	735,457 (RMB 170,600)	As of September 30, 2022, the price paid \$754,468 thousand (RMB 168,650 thousand).	Jiangsu Huaitian Construction Ltd.	-	N/A	N/A	N/A	N/A	Price comparison and price negotiation	Operating purpose	None

Schedule F Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

										(in thousands of New Talwa	an Donars)
Name of company	Related Party	Nature of	Transaction details				Transactions different fro		Notes / Acc	ounts receivable (payable)	Remark
ivaine of company	Realed Failty	Relationship	Purchase / Sale	Amount	Percentage of the purchases / sales	Payment terms	Unit	Payment terms	Ending balance	Percentage of total notes / accounts receivable (payable)	Remark
Jiangsu Win Yield Agriculture Development Co., Ltd.	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Affiliate	Purchase	157,889	68.99%	Payment term 30 days	-	-	19,671	51.88%	(Note)
Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	Affiliate	Sales	(157,889)	62.20%	Payment term 30 days	-	-	(19,671)	66.96%	(Note)

Note: The amount of the transaction had been offset in the consolidated financial statements.

Schedule G Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of Company	Name of Counter-party	Relationship	Ending	Turnover		Overdue	Amounts received	Allowances	Remark
Name of Company	Name of Counter-party	Relationship	balance	rate	Amount	Action taken	in subsequent period	for bad debts	Kelliark
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	Affiliate	478,320	(Note 1)	-	-	-	-	(Note 2)
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Affiliate	159,010	(Note 1)	-	-	-	-	(Note 2)

Note 1: The ending balance was other receivables, which was not applicable for the calculation of turnover rate.

Note 2: The amount of the transaction had been offset in the consolidated financial statements.

Schedule H Business relationships and significant inter-company transactions:

(In thousands of New Taiwan Dollars)

Number			Nature of	Intercompany transactions							
(Note 1)	Name of Company	Name of Counter-party	relationship (Note 2)	Account name	Amount (Note 3)	Trading terms	Percentage of the consolidated net revenue or total assets				
1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	3	Other receivables due from related parties	478,320	no difference with non-related parties	0.68%				
2	Jiangsu Win Yield Agriculture Development Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	478,320	no difference with non-related parties	0.68%				
1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	3	Other receivables due from related parties	159,010	no difference with non-related parties	0.23%				
3	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	159,010	no difference with non-related parties	0.23%				
4	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	3	Sales	157,889	no difference with non-related parties	1.07%				
2	Jiangsu Win Yield Agriculture Development Co., Ltd.	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	3	Purchase	157,889	no difference with non-related parties	1.07%				

Note 1: Company numbering as follows:

Parent company - 0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary - 1

Subsidiary to parent company - 2

Subsidiary to subsidiary - 3

Note 3: The amount of the transaction had been offset in the consolidated financial statements...

Schedule I Information on investments:

The following is the information on investees as of September 30, 2022 (excluding information on investees in mainland China):

(In thousands of New Taiwan Dollars)

	Main		Main	Original inves	tment amount	The en	ding balance at this po	eriod	Net income	J	,
Name of investor	Name of investee	Location	businesses and	The ending balance	The ending balance	Shares	Percentage of	Carrying	(losses)	Investment income (losses)	Remark
			products	at the end	at the beginning	(in thousands)	ownership	value	of investee	meome (losses)	
The Company	WIN SEMI. USA, INC.	California USA	Marketing	8,203	8,203	1,000	100.00%	(22,538)	(11,817)	(11,817)	(Note 1)
"	Win Semiconductors Cayman	Cayman Islands	Investment activities	11,127,774	11,127,774	376,600	100.00%	9,412,465	(1,352,027)	(1,352,027)	(Note 1)
	Islands Co., Ltd.										
"	WIN Venture Capital Corp.	Taiwan	Investment activities	1,040,000	790,000	104,000	100.00%	1,085,992	15,580	15,580	(Note 1)
"	Phalanx Biotech Group, Inc.	Taiwan	Researching, manufacturing and selling of high-density	1,079,169	1,079,169	53,427	73.67%	558,515	(110,480)	(81,385)	(Note 1)
			gene chips and testing service								
"	WIN Chance Investment Corp.	Taiwan	Investment activities	830,000	580,000	87,350	100.00%	916,647	16,870	16,870	(Note 1)
"	WIN Earn Investment Corp.	Taiwan	Investment activities	580,000	580,000	58,000	100.00%	467,952	15,110	15,110	(Note 1)
"	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	6,120,993	6,120,993	65,409	17.08%	7,809,081	1,521,175	235,333	
			copper-clad laminates, prepreg, and electronic components.								
WIN Venture Capital Corp.	Phalanx Biotech Group, Inc.	Taiwan	Researching, manufacturing and selling of high-density	39,600	39,600	1,116	1.54%	29,072	(110,480)	(Note 2)	(Note 1)
			gene chips and testing service								
"	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	713,036	713,036	5,301	1.39%	726,116	1,521,175	(Note 2)	
			copper-clad laminates, prepreg, and electronic components.								
Win Semiconductors Cayman	Rainbow Star Group Limited	British Virgin	Investment activities	62,920	62,920	38	49.30%	56,287	(8,780)	(Note 2)	
Islands Co., Ltd.		Islands									
"	Chainwin Biotech and Agrotech	Cayman Islands	Investment activities	10,905,959	10,905,959	185,054	81.23%	7,990,722	(1,468,560)	(Note 2)	(Note 1)
	(Cayman Islands) Co., Ltd.										
Chainwin Biotech and Agrotech	i-Chainwin Technology (Cayman	"	Investment activities	194,670	194,670	6,500	100.00%	168,181	(153)	(Note 2)	(Note 1)
(Cayman Islands) Co., Ltd.	Islands) Co., Ltd.										
"	Win Lux Biotech (Cayman Islands)	"	Investment activities	15,010	15,010	500	100.00%	12,269	(232)	(Note 2)	(Note 1)
	Co., Ltd.										
"	i-Chainwin Technology Co., Ltd.	Taiwan	Information software services	220,000	220,000	22,000	100.00%	143,852	(9,491)	(Note 2)	(Note 1)
"	Win Lux Biotech Co., Ltd.	Taiwan	Biotechnology services and pharmaceutical testing	100,000	100,000	10,000	100.00%	32,808	(54,954)	(Note 2)	(Note 1)
Phalanx Biotech Group, Inc.	Phalanx Biotech Limited.	Hong Kong	Investment activities	12,125	12,125	=	100.00%	3,772	351	(Note 2)	(Note 1)
"	PhalanxBio, Inc.	USA	Selling of high-density gene chip and test service	208,110	208,110	2,550	100.00%	21	54	(Note 2)	(Note 1)
"	Guzip Biomarkers Corporation	Taiwan	Development and sales of test reagents for endometrial cancer	81,727	81,727	14,238	100.00%	77,274	(1,026)	(Note 2)	(Note 1)
WIN Chance Investment Corp.	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	595,251	595,251	4,702	1.23%	662,731	1,521,175	(Note 2)	
			copper-clad laminates, prepreg, and electronic components.								
WIN Earn Investment Corp.	ITEQ Corporation	Taiwan	"	568,005	568,005	4,230	1.10%	424,898	1,521,175	(Note 2)	

Note 1: The amount of the transaction had been offset in the consolidated financial statements.

Note 2: The share of profit (loss) of the investee company is not reflected herein as such amount is already included in the share of profit (loss) of the investor company.

Schedule J Information on investment in mainland China:

(i) The names of investees in mainland China, the main businesses and products, and other information:

(In thousands of Dollars)

																			(In thousands	s of Dollars)
						nulated outflow					lated outflow			Direct/Indirect	Inv	estment		ing value	Accumulated	
Name of	Main businesses		amount	Method of		vestment from	Ir	ivestment fl	lows		estment from		ome (losses)	percentage of		ne (losses)		the end	remittance of	Remark
investee	and products	of paid	-in capital	investment		iwan at the					wan as of	of the	e investee	ownership by the		4)(Note 6)		is period	earnings in current	
					beginn	ing of this year		tflow	Inflow	Septem	ber 30, 2022			Company				lote 5)	period	
Jiangsu Chainwin Kang Yuan	Developing hog farming technology		3,728,267	(Note 1)		2,748,422		560,600	-		3,309,022		(738,864)	81.23%		(738,864)		2,347,896	-	(Note 10)
Agricultural Development Co., Ltd.	and trading	(RMB	847,767)		(USD	93,043)	(USD	20,000)		(USD	113,043)	(USD	(25,305))		(USD	(25,305))	(USD	73,949)		
Jiangsu Chainwin Agriculture and	Farm feed developing and trading		1,314,369	(Note 1)		1,146,255		145,250	-		1,291,505		(187,493)	81.23%		(187,493)		1,084,507	-	(Note 10)
Animal Technology Co., Ltd.		(USD	43,790)		(USD	38,046)	(USD	5,000)		(USD	43,046)	(USD	(6,297))		(USD	(6,297))	(USD	34,158)		
Jiangsu CM/Chainwin Agriculture	Developing hog farming technology		2,059,210	(Note 1)		1,122,874		-	-		1,122,874		(43,109)	39.80%		(21,123)		671,969	-	
Development Co., Ltd.	and trading	(USD	67,584)		(USD	36,821)				(USD	36,821)	(USD	(1,624))		(USD	(796))	(USD	21,164)		
Jiangsu Win Chance Agriculture	Developing hog farming technology		610,094	(Note 1)		507,992		143,150	-		651,142		(9,788)	81.23%		(9,788)		539,452	-	(Note 10)
Development Co., Ltd.	and trading	(USD	20,200)		(USD	16,569)	(USD	5,000)		(USD	21,569)	(USD	(404))		(USD	(404))	(USD	16,991)		
Jiangsu Merit/Cofcojoycome	Developing hog farming technology		-	(Note 1)		149,664		-	-		149,664	ĺ	-	-		-		-	-	(Note 8)
Agriculture Development Co., Ltd.	and trading				(USD	4,872)				(USD	4,872)	ĺ								
Jiangsu Merit Runfu Agriculture	Developing hog farming technology		72,313	(Note 1)		41,009		-	-		41,009		2	81.23%		2		8,472	-	(Note 10)
Development Co., Ltd.	and trading	(RMB	16,177)		(USD	1,335)				(USD	1,335)	(USD	-)		(USD	-)	(USD	267)		
Jiangsu Win Yield Agriculture	Developing hog farming technology		2,294,135	(Note 1)		1,737,325		361,790	-		2,099,115		(408, 124)	81.23%		(408,124)		1,976,945	-	(Note 10)
Development Co., Ltd.	and trading	(USD	79,500)		(USD	59,500)	(USD	13,000)		(USD	72,500)	(USD	(13,652))		(USD	(13,652))	(USD	62,266)		
Jiangsu Win Shine Agriculture	Logistics management service		345,130	(Note 1)		85,170		-	-		85,170		(9,189)	81.23%		(9,189)		330,517	-	(Note 10)
Development Co., Ltd.		(USD	12,000)		(USD	3,000)				(USD	3,000)	(USD	(319))		(USD	(319))	(USD	10,410)		
Jiangsu Win Boutique Agriculture	Developing hog farming technology		288,100	(Note 1)		-		-	-		-	l	28,592	81.23%		28,592		279,718	-	(Note 10)
Development Co., Ltd.	and trading	(USD	10,000)									(USD	949)		(USD	949)	(USD	8,810)		
Jiangsu Win Sunlight Agriculture	Developing hog farming technology		288,100	(Note 1)		86,430		-	-		86,430	ĺ	29,771	81.23%		29,771		276,064	-	(Note 10)
Development Co., Ltd.	and trading	(USD	10,000)		(USD	3,000)				(USD	3,000)	(USD	989)		(USD	989)	(USD	8,695)		
Jiangsu Win Honor Management	Logistics management service		288,100	(Note 1)		- 1		-	-		- '	ĺ	31,005	81.23%		31,005		309,567	-	(Note 10)
Technology Co., Ltd.		(USD	10,000)									(USD	1,031)		(USD	1,031)	(USD	9,750)		
Jiangsu Win Wonder Agriculture	Developing farming technology		88,173	(Note 3)		-		-	-		-	ĺ	(7,606)	81.23%		(7,606)		79,562	-	(Note 10)
Development Co., Ltd.	and trading	(RMB	20,000)									(RMB	(1,702))		(RMB	(1,702))	(RMB	17,785)		
Jiangsu Win Fortune Agriculture	Developing hog farming technology		276,400	(Note 1)		221,120		-	-		221,120	ĺ	27,058	81.23%		27,058		297,030	-	(Note 10)
Development Co., Ltd.	and trading	(USD	10,000)		(USD	8,000)				(USD	8,000)	(USD	897)		(USD	897)	(USD	9,355)		
Chainwin (Huaian) AIoT Co., Ltd.	Information software services	1	27,860	(Note 1)		27,860		-	-		27,860		2,452	81.23%		2,452		27,593	-	(Note 10)
		(USD	1,000)		(USD	1,000)				(USD	1,000)	(USD	81)		(USD	81)	(USD	869)		ĺ .
Jiangsu Win Advance Bio-Assay Co., Ltd.	Biotechnology testing service	1	111,560	(Note 1)		- 1		-	-		- 1		(1,490)	81.23%		(1,490)		111,460	-	(Note 10)
	5. 2	(USD	4,000)									(USD	(50))		(USD	(50))	(USD	3,511)		
Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and	1	27,680	(Note 1)		27,680		-	-		27,680	1	2,357	81.23%	•	2,357	-	30,472	-	(Note 10)
,	bioassay	(USD	1,000)	. ,	(USD	1,000)				(USD	1,000)	(USD	78)		(USD	78)	(USD	960)		` '
Onearray Biotech (Kunshan) Co., Ltd.	Selling of high density gene chip	1	12,125	(Note 2)		12,125		-	_	-	12,125	1	354	75.21%	-	354	-	3,796	-	(Note 10)
, , , , , , , , , , , , , , , , , , , ,	and test service	(RMB	2,663)	. ,	(USD	420)				(USD	420)	(RMB			(RMB	53)	(RMB	849)		` ′′
		\	=,,		,	.20)				,	.20)	`						,,		
		1																		

(ii) Limitation on investment in mainland China:

(In thousands of Dollars)

Investor	Accumulated Investment in mainland	Investment Amounts Authorized by	Upper Limit on Investment
Company Name	China at the end (Note 7)(Note 8)	Investment Commission, MOEA	(Note 9)
The Company and subsidiaries	9,386,136 (USD 318,989)	, ,	21,225,792

- Note 1: The Group invested in mainland China companies through Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd , which is established in a third region.
- Note 2: The Group invested in mainland China companies through Phalanx Biotech Limited, which is established in a third region.
- Note 3: The Company invested in mainland China companies through Jiansu Win Chance Agriculture Development Co., Ltd.
- Note 4: The amount of net income (losses) was recognized based on the reviewed financial statements of the investee companies.
- Note 5: Carrying value as of September 30, 2022 was with reference to the amount recognized by the investment through subsidiaries to subsidiaries established in a third region.
- Note 6: Investment income (loss) recognized was translated into New Taiwan Dollars at the average exchange rate for the each month from January 1 to September 30, 2022.
- Note 7: The Group acquired Vanchip (Tianjin) Technology Co., Ltd. through a third region, wherein the outflow of investment from Taiwan amounted US\$9,383 thousand (NT\$261,420 thousand).
- Note 8: Jiansu Merit/Cofcojoycome Agriculture Development Co., Ltd. had been liquidated on January 25, 2019. However, according to the regulation of Investment Commission the remittance to mainland China amounting to US\$4,872 thousand (NT\$149,664 thousand) was included in the accumulated investment account.
- Note 9: Amount of upper limit on investment was the higher between sixty percentage of total equity or total consolidated equity.
- Note10: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.
 - (iii) Significant transactions: Please refer Schedule A, Schedule B, Schedule D, Schedule F, Schedule G and Schedule H.

Schedule K Information on major shareholders:

(In shares)

-		(III SHares)
Shareholding Shareholder's Name	Shares	Percentage
Cathay Life Insurance Co.,Ltd.	22,155,000	5.22%